

EU-RISK MANAGEMENT PLAN FOR SARCLISA® (ISATUXIMAB)

Risk Management Plan (RMP) Version number	Version 3.2
Data Lock Point (DLP)	13-JAN-2025
Date of final sign-off	14-JAN-2026

Table 1 - RMP version to be assessed as part of this application

Rationale for submitting an updated RMP	Updated in response to the Day 150 Committee for Medicinal Products for Human Use (CHMP) Assessment Report on the extension of the marketing authorization for Isatuximab (EMA/X/0000281242) - dated 05-Jan-2026, to address the list of outstanding issues on European Union Risk Management Plan (EU-RMP).
Summary of significant changes in this RMP	The following modules and annex have been updated: Cover page, Part I Annex 8
CHMP: Committee for Medicinal Products for Human Use; EMA: European Medicines Agency; EU-RMP: European Union Risk Management Plan; RMP: Risk Management Plan.	

Table 2 - Other RMP versions under evaluation

RMP Version number	Submitted on	Submitted within
Not applicable	-	-
RMP: Risk Management Plan.		

Table 3 - Details of the currently approved RMP

Version number	2.1
Approved with procedure	EMA/H/C/004977/II/0030
Date of approval (opinion date)	14-Nov-2024
EMA: European Medicines Agency; RMP: Risk Management Plan.	

Table 4 - QPPV name and signature

Qualified Person Responsible for Pharmacovigilance (QPPV) name	 ^a
QPPV signature	Electronic signature on file
^a Deputy QPPV by delegation from Heike Schoepper, QPPV for Sanofi. QPPV: Qualified Person Responsible for Pharmacovigilance.	

TABLE OF CONTENT

LIST OF TABLES.....	5
ABBREVIATIONS.....	7
PART I: PRODUCT (S) OVERVIEW.....	10
PART II: MODULE SI - EPIDEMIOLOGY OF THE INDICATION(S) AND TARGET POPULATION(S).....	14
PART II: MODULE SII - NON-CLINICAL PART OF THE SAFETY SPECIFICATION.....	24
PART II: MODULE SIII - CLINICAL TRIAL EXPOSURE.....	30
PART II: MODULE SIV - POPULATIONS NOT STUDIED IN CLINICAL TRIALS.....	40
SIV.1 EXCLUSION CRITERIA IN PIVOTAL CLINICAL STUDIES WITHIN THE DEVELOPMENT PROGRAMME	40
SIV.2 LIMITATIONS TO DETECT ADVERSE REACTIONS IN CLINICAL TRIAL DEVELOPMENT PROGRAMMES.....	43
SIV.3 LIMITATIONS IN RESPECT TO POPULATIONS TYPICALLY UNDER-REPRESENTED IN CLINICAL TRIAL DEVELOPMENT PROGRAMMES.....	44
PART II: MODULE SV - POST-AUTHORIZATION EXPERIENCE.....	52
SV.1 POST-AUTHORIZATION EXPOSURE.....	52
SV.1.1. Method used to calculate exposure	52
SV.1.2. Exposure	52
PART II: MODULE SVI - ADDITIONAL EU REQUIREMENTS FOR THE SAFETY SPECIFICATION	55
SVI.1 POTENTIAL FOR MISUSE FOR ILLEGAL PURPOSES	55
PART II: MODULE SVII - IDENTIFIED AND POTENTIAL RISKS	56
SVII.1 IDENTIFICATION OF SAFETY CONCERNS IN THE INITIAL RMP SUBMISSION	56
SVII.1.1. Risks not considered important for inclusion in the list of safety concerns in the RMP	56
SVII.1.2. Risks considered important for inclusion in the list of safety concerns in the RMP	59
SVII.2 NEW SAFETY CONCERNS AND RECLASSIFICATION WITH A SUBMISSION OF AN UPDATED RMP	60
SVII.3 DETAILS OF IMPORTANT IDENTIFIED RISKS, IMPORTANT POTENTIAL RISKS, AND MISSING INFORMATION	60
SVII.3.1. Presentation of important identified risks and important potential risks.....	60
SVII.3.2. Presentation of the missing information	64
PART II: MODULE SVIII - SUMMARY OF THE SAFETY CONCERNS	65

PART III: PHARMACOVIGILANCE PLAN (INCLUDING POST-AUTHORIZATION SAFETY STUDIES).....	66
III.1 ROUTINE PHARMACOVIGILANCE ACTIVITIES	66
III.2 ADDITIONAL PHARMACOVIGILANCE ACTIVITIES.....	66
III.3 SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES.....	66
PART IV: PLANS FOR POST-AUTHORIZATION EFFICACY STUDIES.....	67
PART V: RISK MINIMIZATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMIZATION ACTIVITIES)	68
V.1 ROUTINE RISK MINIMIZATION MEASURES	68
V.2 ADDITIONAL RISK MINIMIZATION MEASURES	68
V.3 SUMMARY OF RISK MINIMIZATION MEASURES	69
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN	71
I. THE MEDICINE AND WHAT IT IS USED FOR.....	71
II. RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERIZE THE RISKS.....	72
II.A List of important risks and missing information	72
II.B Summary of important risks	73
II.C Post-authorization development plan.....	74
II.C.1 Studies which are conditions of the marketing authorization.....	74
II.C.2 Other studies in post-authorization development plan.....	74
REFERENCES	75
PART VII: ANNEXES	80

LIST OF TABLES

Table 1 - RMP version to be assessed as part of this application	2
Table 2 - Other RMP versions under evaluation	2
Table 3 - Details of the currently approved RMP	2
Table 4 - QPPV name and signature	2
Table 5 - Product Overview	10
Table 6 - Epidemiology of Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant	14
Table 7 - Key safety findings from non-clinical studies and relevance to human usage.....	26
Table 8 - Duration of exposure – Cumulative and by indication (IV formulation).....	31
Table 9 - Exposure by age group and gender – Cumulative and by indication (IV formulation).....	32
Table 10 - Exposure by age group and gender (person-years) – Cumulative and by indication (IV formulation).....	32
Table 11 - Exposure by ethnic origin – Cumulative and by indication (IV formulation).....	33
Table 12 - Exposure by ethnic origin (person-years) – Cumulative and by indication (IV formulation)	33
Table 13 - Exposure by race – Cumulative and by indication (IV formulation)	34
Table 14 - Exposure by race (person-years) – Cumulative and by indication (IV formulation).....	35
Table 15 - Duration of exposure - Cumulative and by treatment (SC formulation)	35
Table 16 - Exposure by age group and gender - Cumulative and by treatment (SC formulation).....	36
Table 17 - Exposure by age group and gender (person-years) - Cumulative and by treatment (SC formulation).....	37
Table 18 - Exposure by ethnic origin – Cumulative and by treatment (SC formulation)	37
Table 19 - Exposure by ethnic origin (person-years) – Cumulative and by treatment (SC formulation).....	38
Table 20 - Exposure by race – Cumulative and by treatment (SC formulation).....	38
Table 21 - Exposure by race (person-years) – Cumulative and by treatment (SC formulation)	39
Table 22 - Important exclusion criteria in pivotal studies in the development programme	40
Table 23 - Exposure of special populations included or not in clinical trial development programmes	44
Table 24 - Important identified risk considered for inclusion in the list of safety concerns: Interference with indirect antiglobulin test (indirect Coombs' test) and possible resulting adverse clinical consequences for the patient (bleeding due to transfusion delay, transfusion haemolysis).....	59
Table 25 - Important potential risk considered for inclusion in the list of safety concerns: Viral reactivation.....	60
Table 26 - Important identified risk: Interference for blood typing (minor antigen) (positive indirect Coombs' test).....	60
Table 27 - Important potential risk: Viral Reactivation.....	62
Table 28 - Summary of the safety concerns.....	65
Table 29 - Description of routine risk minimization measures by safety concern	68
Table 30 - Additional risk minimization measures	68

Table 31 - Summary table of pharmacovigilance activities and risk minimization activities by safety concern	69
Table 32 - List of important risks and missing information	73
Table 33 - Important identified risk with corresponding risk minimization activities: Interference for blood typing (minor antigen) (positive indirect Coombs' test)	73
Table 34 - Important potential risk with corresponding risk minimization activities: Viral reactivation	73

ABBREVIATIONS

ACTH:	Adrenocorticotrophic Hormone
ADA:	Anti-Drug Antibody
AE:	Adverse Event
ALT:	Alanine Aminotransferase
aRMM:	Additional Risk Minimization Measure
ASCT:	Autologous Stem Cell Transplant
ASIR:	Age-Standardized Incidence Rate
AST:	Aspartate Aminotransferase
ATC:	Anatomical Therapeutic Chemical
B/R:	Benefit/Risk
BBB:	Blood Brain Barrier
C1P1F1:	Cell 1, Process 1, Formulation 1
C1P2F2:	Cell 1, Process 2, Formulation 2
CAR T:	Chimeric Antigen Receptor T-cell
CD:	Cluster of Differentiation
CHMP:	Committee for Medicinal Products for Human Use
CHO:	Chinese Hamster Ovary
CI:	Confidence Interval
CNS:	Central Nervous System
CRS:	Cytokine Release Syndrome
CYP:	Cytochrome P450
DALA:	Drug Abuse Liability Assessment
DaraKd:	Daratumumab/Carfilzomib/Dexamethasone
DaraPd:	Daratumumab/Pomalidomide/Dexamethasone
DaraRd:	Daratumumab/Lenalidomide/Dexamethasone
DaraVd:	Daratumumab/Bortezomib/Dexamethasone
DaraVMP:	Daratumumab/Bortezomib/Melphalan/Prednisone
DaraVTD:	Daratumumab/Bortezomib/Thalidomide/Dexamethasone
DDI:	Drug-Drug Interaction
DLP:	Data Lock Point
DNA:	Deoxyribonucleic Acid
DRd:	Daratumumab/Lenalidomide/Low-dose Dexamethasone
DTT:	Dithiothreitol
ECG:	Electrocardiogram
ECO:	European Cancer Observatory
ECOG:	Eastern Cooperative Oncology Group
e-CTD:	Electronic Common Technical Document
EEA:	European Economic Area
eGFR:	Estimated Glomerular Filtration Rate
EMA/EMEA:	European Medicines Agency
EPAR:	European Public Assessment Report
ESMO:	European Society for Medical Oncology
ESRD:	End-Stage Renal Disease

EU:	European Union
EU-RMP:	European Union Risk Management Plan
FSH:	Follicle Stimulating Hormone
GH:	Growth Hormone
GLOBOCAN:	Global Cancer Observatory
GLP:	Good Laboratory Practice
GVP:	Good Pharmacovigilance Practices
HBV:	Hepatitis B Virus
HCP:	Healthcare Professional
HER:	Health Electronic Records
HIV:	Human Immunodeficiency Virus
HR:	Hazard Ratio
IARC:	International Agency for Research on Cancer
IAT:	Indirect Antiglobulin Test
ICD:	International Classification of Diseases
ICH:	International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
IgG:	Immunoglobulin G
IMiD:	Immunomodulatory Agent
INN:	International Nonproprietary Name
IR:	Infusion Reaction
IRd:	Izaxomib/Lenalidomide/Low-dose Dexamethasone
Isa-Kd:	Isatuximab/Carfilzomib/Dexamethasone
Isa-Pd:	Isatuximab/Pomalidomide/Dexamethasone
Isa-VRd:	Isatuximab/Bortezomib/Lenalidomide/Dexamethasone
ISS:	International Staging System
IV:	Intravenous
IVRd:	Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone
Kd:	Carfilzomib/Dexamethasone
KRd:	Carfilzomib/Lenalidomide/Dexamethasone
LDH:	Lactate Dehydrogenase
LH:	Luteinizing Hormone
mAb:	Monoclonal Antibody
MAH:	Marketing Authorization Holder
MARCO:	Margin Consolidated
MM:	Multiple Myeloma
MRD:	Modification of Diet in Renal Disease
NAb:	Neutralizing Antibody
NCCN:	National Comprehensive Cancer Network
NDMM:	Newly Diagnosed Multiple Myeloma
NDMM-T1:	Newly Diagnosed Multiple Myeloma patients not eligible to Stem Cell Transplant
NE:	Not Estimable
NK:	Natural Killer
NOAEL:	No Observed Adverse Effect Level
OBDS:	On-Body Delivery System
OR:	Odds Ratio
OS:	Overall Survival

PASS:	Post-Authorization Safety Study
PCd:	Pomalidomide/Cyclophosphamide/Dexamethasone
PCL:	Plasma Cell Leukemia
Pd:	Pomalidomide/Dexamethasone
PFS:	Progression Free Survival
PI:	Proteasome Inhibitor
PK:	Pharmacokinetic
PL:	Package Leaflet
PSA:	Prostate Specific Antigen
PSUR:	Periodic Safety Update Report
PVd:	Pomalidomide/Bortezomib/Dexamethasone
Q2W:	Every 2 Weeks
QPPV:	Qualified Person Responsible for Pharmacovigilance
QW:	Once Weekly
RBC:	Red Blood Cell
RCT:	Randomized Clinical Trials
Rd:	Lenalidomide/Dexamethasone
Rd-Elo:	Elotuzumab/Lenalidomide/Low-dose Dexamethasone
RhD:	Rhesus Factor D
R-ISS:	Revised International Staging System
RMP:	Risk Management Plan
RMS:	Risk Minimization Strategy
RRMM:	Relapsed/Refractory Multiple Myeloma
SC:	Subcutaneous
SCS:	Summary of Clinical Safety
Sd:	Selinexor/Dexamethasone
SEER:	Surveillance Epidemiology and End Results
SMQ:	Standardized MedDRA Query
SOC:	Standard of Care
SPM:	Second Primary Malignancy
SVD:	Selinexor/Bortezomib/Dexamethasone
TLS:	Tumour Lysis Syndrome
TSH:	Thyroid Stimulating Hormone
UI:	Uncertainty Interval
UK:	United Kingdom
ULN:	Upper Limit of Normal
US:	United States
VCD:	Bortezomib/Cyclophosphamide/Dexamethasone
Vd-Pano:	Panobinostat/Bortezomib/Dexamethasone
VenVD:	Venetoclax/Bortezomib/Dexamethasone
VMP:	Bortezomib/Melphalan/Prednisone
VRd:	Bortezomib/Lenalidomide/Dexamethasone
VZV:	Varicella Zoster Virus

PART I: PRODUCT (S) OVERVIEW

Table 5 - Product Overview

Active substance(s) (International Nonproprietary Name [INN] or common name)	Isatuximab
Pharmacotherapeutic group(s) (Anatomical Therapeutic Chemical [ATC] Code)	Antineoplastic agents, monoclonal antibodies (ATC code: L01FC02)
Marketing Authorization Holder (MAH)	Sanofi Winthrop Industrie
Medicinal products to which this RMP refers	1
Invented name(s) in European Economic Area (EEA)	SARCLISA
Marketing authorization procedure	Centralized procedure
Brief description of the product	<u>Chemical class:</u> Immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
	<u>Summary of mode action:</u> Isatuximab binds to a specific extracellular epitope of cluster of differentiation (CD38) receptor and triggers several mechanisms leading to the death of CD38 expressing tumor cells.
	<u>Important information about its composition:</u> Isatuximab, L-arginine monohydrochloride, Sucrose, Poloxamer 188, L-histidine/ L-histidine hydrochloride monohydrate, Water for injections. Isatuximab is a well-characterized recombinant protein product expressed in Chinese Hamster Ovary (CHO) cells manufactured without the direct use of animal-derived raw materials.
Hyperlink to the product information	Refer to electronic common technical document (e-CTD) sequence 0079, Module 1.3.1 English proposed Product Information.
Indication(s) in the EEA	<u>Current:</u> SARCLISA (intravenous [IV] administration) is indicated: • <i>in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.</i> • <i>in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).</i> • <i>in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.</i>

	• <i>in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.</i> <u>Proposed:</u> SARCLISA is indicated: • <i>in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.</i> • <i>in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).</i> • <i>in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.</i> • <i>in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.</i>																
Dosage in the EEA	<u>Current:</u> The recommended dose of SARCLISA is 10 mg/kg body weight administered as an intravenous infusion in combination with pomalidomide and dexamethasone (Isa-Pd) or in combination with carfilzomib and dexamethasone (Isa-Kd), or in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd). SARCLISA dosing schedules are provided in Table 5a, Table 5b and Table 5c: Table 5a - SARCLISA dosing schedule in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone <table border="1"> <thead> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> </thead> <tbody> <tr> <td>Cycle 1 (28-day cycle)</td><td>Days 1, 8, 15 and 22 (weekly)</td></tr> <tr> <td>Cycle 2 and beyond (28-day cycle)</td><td>Days 1, 15 (every 2 weeks)</td></tr> </tbody> </table> Each treatment cycle consists of a 28-day period. Treatment is repeated until disease progression or unacceptable toxicity. Table 5b - SARCLISA dosing schedule in combination with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) (IMROZ) <table border="1"> <thead> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> </thead> <tbody> <tr> <td>Cycle 1 (42-day cycle)</td><td>Days 1, 8, 15, 22, and 29</td></tr> <tr> <td>Cycles 2 to 4 (42-day cycles)</td><td>Days 1, 15, and 29 (every 2 weeks)</td></tr> <tr> <td>Cycles 5 to 17 (28-day cycles)</td><td>Days 1, 15 (every 2 weeks)</td></tr> <tr> <td>Cycles 18 and beyond (28-day cycles)</td><td>Day 1 (every 4 weeks)</td></tr> </tbody> </table> ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma.	Cycles	Dosing schedule	Cycle 1 (28-day cycle)	Days 1, 8, 15 and 22 (weekly)	Cycle 2 and beyond (28-day cycle)	Days 1, 15 (every 2 weeks)	Cycles	Dosing schedule	Cycle 1 (42-day cycle)	Days 1, 8, 15, 22, and 29	Cycles 2 to 4 (42-day cycles)	Days 1, 15, and 29 (every 2 weeks)	Cycles 5 to 17 (28-day cycles)	Days 1, 15 (every 2 weeks)	Cycles 18 and beyond (28-day cycles)	Day 1 (every 4 weeks)
Cycles	Dosing schedule																
Cycle 1 (28-day cycle)	Days 1, 8, 15 and 22 (weekly)																
Cycle 2 and beyond (28-day cycle)	Days 1, 15 (every 2 weeks)																
Cycles	Dosing schedule																
Cycle 1 (42-day cycle)	Days 1, 8, 15, 22, and 29																
Cycles 2 to 4 (42-day cycles)	Days 1, 15, and 29 (every 2 weeks)																
Cycles 5 to 17 (28-day cycles)	Days 1, 15 (every 2 weeks)																
Cycles 18 and beyond (28-day cycles)	Day 1 (every 4 weeks)																

	Each treatment cycle consists of a 42-day period from cycle 1 to 4, and of a 28-day period from cycle 5. Treatment is repeated until disease progression or unacceptable toxicity. Table 5c - SARCLISA dosing schedule in combination with bortezomib, lenalidomide, and dexamethasone for patients with NDMM who are eligible for ASCT (GMMG-HD7) <table border="1"> <thead> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> </thead> <tbody> <tr> <td colspan="2"><i>Induction treatment</i></td></tr> <tr> <td>Cycle 1 (42-day cycle)</td><td>Days 1, 8, 15, 22, and 29</td></tr> <tr> <td>Cycles 2 to 3 (42-day cycles)</td><td>Days 1, 15, and 29 (every 2 weeks)</td></tr> <tr> <td colspan="2"><i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i></td></tr> <tr> <td colspan="2">ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma; SOC: Standard of Care.</td></tr> </tbody> </table> Each treatment cycle consists of a 42-day period. For other medicinal products that are administered with SARCLISA, see section 5.1 and the respective current summary of product characteristics. <u>Missed dose</u> The administration schedule must be carefully followed. If a planned dose of SARCLISA is missed, administer the dose as soon as possible and adjust the treatment schedule accordingly, maintaining the treatment interval. <u>Proposed:</u> The recommended dose of SARCLISA subcutaneous is 1400 mg administered as subcutaneous injection with CirCLIQ On-Body Delivery System (OBDS) or with a syringe and infusion set for manual administration. SARCLISA subcutaneous is administered in combination with pomalidomide and dexamethasone (Isa-SC + Pd) or in combination with carfilzomib and dexamethasone (Isa-SC + Kd), or in combination with bortezomib, lenalidomide, and dexamethasone (Isa-SC + VRd). SARCLISA subcutaneous dosing schedules are provided in Table 5d, Table 5e and Table 5f: Table 5d: Dosing schedule in combination with pomalidomide and dexamethasone or in combination with carfilzomib and dexamethasone <table border="1"> <thead> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> </thead> <tbody> <tr> <td>Cycle 1 (28-day cycle)</td><td>1400 mg weekly; days 1, 8, 15 and 22</td></tr> <tr> <td>Cycle 2 and beyond (28-day cycle)</td><td>1400 mg every 2 weeks; days 1 and 15</td></tr> </tbody> </table> Each treatment cycle consists of a 28-day period. Treatment is repeated until disease progression or unacceptable toxicity. Table 5e: Dosing schedule in combination with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) <table border="1"> <thead> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> </thead> <tbody> <tr> <td>Cycle 1 (42-day cycle)</td><td>1400 mg; days 1, 8, 15, 22, and 29</td></tr> </tbody> </table>	Cycles	Dosing schedule	<i>Induction treatment</i>		Cycle 1 (42-day cycle)	Days 1, 8, 15, 22, and 29	Cycles 2 to 3 (42-day cycles)	Days 1, 15, and 29 (every 2 weeks)	<i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i>		ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma; SOC: Standard of Care.		Cycles	Dosing schedule	Cycle 1 (28-day cycle)	1400 mg weekly; days 1, 8, 15 and 22	Cycle 2 and beyond (28-day cycle)	1400 mg every 2 weeks; days 1 and 15	Cycles	Dosing schedule	Cycle 1 (42-day cycle)	1400 mg; days 1, 8, 15, 22, and 29
Cycles	Dosing schedule																						
<i>Induction treatment</i>																							
Cycle 1 (42-day cycle)	Days 1, 8, 15, 22, and 29																						
Cycles 2 to 3 (42-day cycles)	Days 1, 15, and 29 (every 2 weeks)																						
<i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i>																							
ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma; SOC: Standard of Care.																							
Cycles	Dosing schedule																						
Cycle 1 (28-day cycle)	1400 mg weekly; days 1, 8, 15 and 22																						
Cycle 2 and beyond (28-day cycle)	1400 mg every 2 weeks; days 1 and 15																						
Cycles	Dosing schedule																						
Cycle 1 (42-day cycle)	1400 mg; days 1, 8, 15, 22, and 29																						

	Cycles 2 to 4 (42-day cycles) 1400 mg every 2 weeks; days 1, 15, and 29 Cycles 5 to 17 (28-day cycles) 1400 mg every 2 weeks; days 1 and 15 Cycles 18 and beyond (28-day cycles) 1400 mg every 4 weeks; day 1 ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma. <i>Treatment is repeated until disease progression or unacceptable toxicity.</i> Table 5f: Dosing schedule in combination with bortezomib, lenalidomide, and dexamethasone for patients with NDMM who are eligible for ASCT <table> <tr> <th>Cycles</th><th>Dosing schedule</th></tr> <tr> <td colspan="2"><i>Induction treatment</i></td></tr> <tr> <td>Cycle 1 (42-day cycle)</td><td>1400 mg; days 1, 8, 15, 22, and 29</td></tr> <tr> <td>Cycles 2 to 3 (42-day cycles)</td><td>1400 mg every 2 weeks; days 1, 15, and 29</td></tr> <tr> <td colspan="2"><i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i></td></tr> </table> ASCT: Autologous Stem Cell Transplant; NDMM: Newly Diagnosed Multiple Myeloma; SOC: Standard of Care. <i>Each treatment cycle consists of a 42-day period.</i> <i>Patients may start treatment using intravenous or subcutaneous isatuximab. Patients currently receiving intravenous isatuximab may switch to subcutaneous isatuximab, at any time during their treatment, once cycle 1 is completed.</i> <u>Missed dose</u> <i>The administration schedule must be carefully followed. If a planned dose of SARCLISA subcutaneous is missed, administer the dose as soon as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.</i>	Cycles	Dosing schedule	<i>Induction treatment</i>		Cycle 1 (42-day cycle)	1400 mg; days 1, 8, 15, 22, and 29	Cycles 2 to 3 (42-day cycles)	1400 mg every 2 weeks; days 1, 15, and 29	<i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i>	
Cycles	Dosing schedule										
<i>Induction treatment</i>											
Cycle 1 (42-day cycle)	1400 mg; days 1, 8, 15, 22, and 29										
Cycles 2 to 3 (42-day cycles)	1400 mg every 2 weeks; days 1, 15, and 29										
<i>Stop for intensification treatment (high dose chemotherapy and ASCT) followed by SOC maintenance treatment</i>											
Pharmaceutical form(s) and strength(s)	<u>Current:</u> Concentrate for solution for infusion, 20 mg/mL.										
	<u>Proposed:</u> Solution for subcutaneous injection, 1400 mg/10 mL.										
Is/will the product (be) subject to additional monitoring in the European Union (EU)?	No										

ASCT: Autologous Stem Cell Transplant; ATC: Anatomical Therapeutic Chemical; CD: Cluster of Differentiation; CHO: Chinese Hamster Ovary; e-CTD: Electronic Common Technical Document; EEA: European Economic Area; EU: European Union; IgG: Immunoglobulin G; INN: International Nonproprietary Name; Isa-Kd: Isatuximab/Carfilzomib/Dexamethasone; Isa-Pd: Isatuximab/Pomalidomide/Dexamethasone; Isa-VRd: Isatuximab/Bortezomib/Lenalidomide/Dexamethasone; IV: Intravenous; mAb: Monoclonal Antibody; MAH: Marketing Authorization Holder; NDMM: Newly Diagnosed Multiple Myeloma; OBDS: On-Body Delivery System; RMP: Risk Management Plan; SC: Subcutaneous; SOC: Standard of Care.

PART II: SAFETY SPECIFICATION

PART II: MODULE SI - EPIDEMIOLOGY OF THE INDICATION(S) AND TARGET POPULATION(S)

Isatuximab is a monoclonal antibody indicated to treat multiple myeloma (MM). The detailed indications are available in [\[Part I\]](#).

The epidemiology of the disease is summarized in [Table 6](#).

Table 6 - Epidemiology of Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
Incidence	The worldwide age standardized incidence rate (ASIR) of MM extracted from the Global Cancer Observatory in 2020 (1) was 1.78 (95% uncertainty interval [UI] 1.69-1.87) per 100 000 people globally, corresponding to 176 404 new cases. The three world regions with the highest ASIR are Australia and New Zealand (4.86/100 000 persons; 95% UI: 4.66-5.07), North America (4.74/100 000 persons; 95% UI: 4.69-4.79) and Northern Europe (3.82/100 000 persons; 95% UI: 3.71-3.93). In 2019, the ASIR in Eastern Europe was 1.57 per 100 000 persons (95% UI: 1.35-1.78), 2.13 (95% UI: 1.69-2.46) in Central Europe, and 4.24 (95% UI: 3.51-4.90) in Western Europe. Age standardized incidence rate (per 100 000 persons) in High-income North America was 1.49 (95% UI: 1.42-5.87), in Tropical Latin America was 2.06 (95% UI: 1.78-2.22) and in Southern Latin America was 2.66 (95% UI: 2.08-3.41). Age standardized incidence rate lower than 1/100 000 were reported in Asia except in High-income Asia Pacific where ASIR was 1.96 (95% UI: 1.58-2.30) (2) Regarding trends, Huang et al (1) reported the highest European increase (average annual increase >4%) in Iceland, Denmark, Germany and Malta. In Asia, the highest increase was reported in Kuwait and Thailand. For the EU as a whole, MM incidence is projected to increase from approximately 35 000 new cases to over 43 000 by 2030. (3) Observational studies in France (4) (2013 - 2017) and in the United States (US) (5) (2011-2021) among adults newly diagnosed MM with a documented first-line therapy initiation reported that 71% and 76% of patients did not receive a ASCT. In the US study, ASCT was less frequent in patients aged 70 years or more than those aged less than 70 years (7% vs 45%). D'Agostino et al (6) published in 2023 a study of 10 843 NDMM patients included in randomized clinical trial (RCT)s from 2005 to 2016. Depending on studies, the proportion of NDMM patients not eligible to ASCT ranged from 35% to 47%.
Prevalence	The International Agency for Research on Cancer (IARC) using Globocan 2020 (7) reported a 5-year worldwide prevalence of 450 579, distributed as follows: • Asia: 150 210, • Europe: 138 083 • Northern America: 100 432 • Latin America and Caribbean: 36 867 • Africa: 16 363 • Oceania: 8624. The 1-year prevalence of MM in the EU, based on data from the IARC, was 4.3/100 000 population, resulting in approximately 39 517 cases.

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
	The estimated 10-year prevalence rate in 2016 available from the Nordic EU countries, Belgium and the United Kingdom (UK) are 31.8, 32.4 and 30.0/100 000 individuals. (IARC data) (8)
Demographics of the population in the authorized indication	<u>In Multiple Myeloma</u> <u>Sex:</u> The global ASIR reported from the GLOBOCAN statistics in 2020 (1) was 2.2/100 000 for males and 1.5/100 000 for females. Multiple Myeloma is approximately 1.5 times more common among men than in women. The cumulative risk of being diagnosed from birth to age 74 is 0.24% among men and 0.17% among women. (9) <u>Age gradient:</u> The crude incidence rates in 2018 were 1.6 per 10 000 and 24.4 per 10 000 in individuals aged 0-64 years and 64 years or more respectively. Multiple Myeloma is typically observed in older adults with the median age being 69 in the US. (9) In term of prevalence, the age group 65-85 years old represents about 65% of all prevalent cases (IARC). <u>Ethnicity:</u> Based on the US cancer registries, blacks showed a substantially higher incidence of MM than that of whites over the three decades (9.9/100 000 versus 4.2 in 1981-1990, 10.1 versus 4.3 in 1991-2000, and 9.9 versus 4.3 in 2001-2010), and people of other races showed the lowest MM incidence (3.1 in 1981-1990, 3.2 in 1991-2000, and 3.2 in 2001-2010). (10) The discrepancy is even higher among younger black patients below age 50 (over 3 times), indicating a younger onset of disease on average among black patients. In addition, there is a greater risk of mortality among black patients with MM in contrast to Caucasians. Asians and Pacific Islanders appeared to have a decreased risk of MM, with an incidence of 6.0/100 000 among men and 3.2/100 000 among women. (9) Older age, positive family history, male sex, black race, and genetic factors have been described as risk factors for the disease. Underlying germline predisposing mutations have yet to be determined in MM. (9) Monoclonal gammopathy of undetermined significance is a condition that precedes MM and is the most important factor associated with the development of MM. Regarding environmental factors, exposure to benzene, petroleum products, and ionizing radiation, as well as agricultural or industrial occupation have been acknowledged, whereas tobacco smoking, obesity, and dietary characteristics are probably less implicated. (11) <u>About pregnancy:</u> Multiple Myeloma is extremely uncommon during pregnancy. Hematologic malignancies represent 25% of the cancers complicating pregnancy. In women aged 15 to 24 years, the most frequent malignant tumor is Hodgkin's lymphoma and the second is leukemia with an incidence reported at 1:75 000 to 1:10 000. (12) <u>In Newly Diagnosed Multiple Myeloma patients ineligible to Stem Cell Transplant (NDMM-TI)</u> The following table displays demographics (13) of 17 731 US NDMM patients aged 45 years and older identified in electronic health record (Medicare and Optum) who did not receive a stem cell transplantation and received at least one line of treatment between 2007 and 2018, and of 178 NDMM aged 65 years or older, considered not eligible to ASCT by the treating physician and who were initiated with either a

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant																														
	daratumab (DRd) or a bortezomib (VRd) triplet combination (TAURUS Chart review [14]). Table 6a - Demographic characteristics of US NDMM-TI patients in claims databases <table><tr><th></th><th>US HER (N = 17 731)</th><th colspan="2">TAURUS</th></tr><tr><th></th><th></th><th>DRd (N = 99)</th><th>VRd (N = 79)</th></tr><tr><td>Mean age ± SD [median]</td><td>71.0 ± 9.83</td><td>76.4 ± 6.0 [77.0]</td><td>75.8 ± 6.0 [75.0]</td></tr><tr><td>Women</td><td>49.5%</td><td>45.5%</td><td>55.7%</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td></tr><tr><td> White</td><td rowspan="4">Not available</td><td>55.6%</td><td>51.9%</td></tr><tr><td> Black / African American</td><td>13.1%</td><td>19.0%</td></tr><tr><td> Other or Unknown</td><td>31.3%</td><td>29.1%</td></tr></table> DRd: Daratumumab/Lenalidomide/Low-dose Dexamethasone; HER: Health Electronic Records; N: Number of patients; NDMM-TI: Newly Diagnosed Multiple Myeloma patients not eligible to Stem Cell Transplant; SD: Standard Deviation; US: United States; VRd: Bortezomib/Lenalidomide/Dexamethasone.		US HER (N = 17 731)	TAURUS				DRd (N = 99)	VRd (N = 79)	Mean age ± SD [median]	71.0 ± 9.83	76.4 ± 6.0 [77.0]	75.8 ± 6.0 [75.0]	Women	49.5%	45.5%	55.7%	Ethnicity				White	Not available	55.6%	51.9%	Black / African American	13.1%	19.0%	Other or Unknown	31.3%	29.1%
	US HER (N = 17 731)	TAURUS																													
		DRd (N = 99)	VRd (N = 79)																												
Mean age ± SD [median]	71.0 ± 9.83	76.4 ± 6.0 [77.0]	75.8 ± 6.0 [75.0]																												
Women	49.5%	45.5%	55.7%																												
Ethnicity																															
White	Not available	55.6%	51.9%																												
Black / African American		13.1%	19.0%																												
Other or Unknown		31.3%	29.1%																												
Main existing treatment options		<u>Newly Diagnosed Multiple Myeloma (NDMM):</u> ESMO GUIDELINES: recommendations for MM front-line therapy, no eligibility for ASCT (15) <u>First option:</u> • DaraRd [I, A] • DaraVMP [I, A] • VRd [I, A] <u>If first option is not available:</u> • VMP [I, A] • Rd [I, A] NCCN Guidelines: primary therapy for non-transplant candidates (16) Preferred Regimens • Daratumumab/lenalidomide/dexamethasone (category 1)Isatuximab-irfc/bortezomib/lenalidomide/dexamethasone (for patients <80 years old who are not frail) (category 1) • Lenalidomide/bortezomib/dexamethasone (category 1) <u>Relapsed /Refractory Multiple Myeloma (RRMM)</u> ESMO GUIDELINES: Second-line options for MM patients who received VRd and Dara-based front-line therapies (15) • Second-line options after VRd - Lenalidomide-sensitive: KRd [I, A] / DaraRd [I, A] / EloRd [I, A] / PomVd [I, A] / DaraKd [I, A] / IsaKd [I, A] / IxaRd [I, A] / SVd [I, A]																													

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
	- Lenalidomide-refractory: PomVd [I, A] / EloRd / DaraKd [I, A] / IsaKd [I, A] / SVd [I, A] - Bortezomib-sensitive: KRd [I, A] / DaraRd [I, A] / EloRd [I, A] / PomVd [I, A] / DaraKd [I, A] / DaraVd [I, A] / IsaKd [I, A] / SVd [I, A] / VenVd [I, A] - Lenalidomide and bortezomib-refractory: DaraKd [I, A] / IsaKd [I, A] • Second-line options after DaraRD - Lenalidomide-sensitive: PomVd / Kd / EloRd / KRd / IxaRd / SVd VenVd - Lenalidomide-refractory: PomVd/ Kd / SVd/ VenVd • Second-line options after DaraVMP or DaraVTD - Bortezomib-sensitive: EloRd / KRd/ IxaRd / VRd / SVd / Kd / VenVd - Bortezomib-refractory: EloRd NCCN Guidelines: Therapy for previously treated MM Relapsed/Refractory disease after 1-3 prior therapies (16) Preferred Regimens • Anti-CD38 refractory - Carfilzomib/lenalidomide/dexamethasone - Carfilzomib/pomalidomide/dexamethasone - Pomalidomide/bortezomib/dexamethasone After two prior therapies including lenalidomide and a PI - Elotuzumab/pomalidomide/dexamethasone After two prior therapies including an IMiD and a PI and with disease progression on/within 60 days of completion of last therapy - Ixazomib/pomalidomide/dexamethasone • Bortezomib-refractory: - Carfilzomib/lenalidomide/dexamethasone - Daratumumab/carfilzomib/dexamethasone - Daratumumab/lenalidomide/dexamethasone - Isatuximab-irfc/carfilzomib/dexamethasone - Carfilzomib/pomalidomide/dexamethasone After one prior therapy including lenalidomide and a PI - Daratumumab/pomalidomide/dexamethasone - Elotuzumab/pomalidomide/dexamethasone After two prior therapies including lenalidomide and a PI - Isatuximab-irfc/pomalidomide/dexamethasone

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
	• Lenalidomide-refractory: - Daratumumab/bortezomib/dexamethasone - Daratumumab/carfilzomib/dexamethasone - Isatuximab-irfc/carfilzomib/dexamethasone - Pomalidomide/bortezomib/dexamethasone - Carfilzomib/pomalidomide/dexamethasone <i>After one prior therapy including lenalidomide and a PI</i> - Daratumumab/pomalidomide/dexamethasone <i>After two prior therapies including lenalidomide and a PI</i> - Isatuximab-irfc/pomalidomide/dexamethasone - Elotuzumab/pomalidomide/dexamethasone <i>After two prior therapies including an IMiD and a PI and with disease progression on/within 60 days of completion of last therapy.</i> - Ixazomib/pomalidomide/dexamethasone • CAR T-Cell Therapy: <i>After one prior line of therapy including IMiD and a PI, and refractory to lenalidomide</i> - Ciltacabtagene autoleucel <i>After two prior lines of therapies including an IMiD, an anti-CD38 monoclonal antibody and a PI</i> - Idecabtagene vicleucel NCCN Guidelines: Therapy for previously treated MM Relapsed/Refractory disease after 3 prior lines of therapy (16) Preferred Regimens • CAR T-cell Therapy: - Ciltacabtagene autoleucel - Idecabtagene vicleucel <i>After at least four prior therapies, including an anti-CD38 monoclonal antibody, a PI, and an IMiD</i> • Bispecific Antibodies: - Elranatamab - Talquetamab - Teclistamab
Natural history of the indicated condition in the untreated population	Although an overall decrease in mortality overtime was observed, the MM remains an incurable disease. Survival in hematological cancers (17) was studied in the Nordic

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
including mortality and morbidity	European countries from 2012 to 2016. The study showed a relative 5-year survival in MM ranging from 43% in Finland to 55% in Denmark. Multiple Myeloma is a heterogenous disease characterized by subsequent relapses in which the burden of the disease and previous treatments received could limit subsequent lines of therapy, as described in treatment guidelines (18). The disease becomes more aggressive after each relapse and the time between relapses is shorter, which means less duration of response per late line of treatment that could lead into treatment refractoriness. Progression free survival (PFS) is shorter after each treatment line and the prognosis of the patients gets worse. Increasing the duration of treatment at relapse has a positive impact in the overall survival (OS) and in the clinical evolution of the disease. A retrospective study of 598 Japanese NDMM patients not eligible for transplant (19) with a median follow-up of 31.3 months reported a median PFS ranging from 12.7 to 31.7 months depending on the treatment received. Overall survival ranged from 43.9 to 79.8 months and was not reached in one treatment regimen. A French retrospective (20) study published in 2019 and assessing 200 RRMM patients showed that a half of RRMM patients were deceased after a median follow-up of 52 months. The median PFS from the second line treatment initiation was 21.4 (15.5; 25.0) months and the median OS was 59.4 (38.8; NE). Among patients initiating the 3rd line of treatment, the median PFS was 12.8 (9.0; 16.8) months and the median OS was 31.9 (23.4; 53.3) months. 20% to 25% MM patients will present with high-risk disease and 20% to 50% have renal impairment which are less responsive to the available treatment and continues to negatively impact PFS and OS, despite advances in treatment. Staging: Using Fluorescence in situ hybridization analysis as a part of the routine evaluation, high risk MM is defined as having at least one of the mutations related with poor prognosis including; t(4;14) t(14;16), t(14;20), del 17p, p53 mutation, gain 1q and del 1p. M-Smart MM risk stratification guidelines proposed by the Mayo Clinic describes the presence of two of the high-risk genetic abnormalities defined as double hit MM and having any three high-risk genetic abnormalities as triple hit MM. (21) The revised international staging system (R-ISS) is currently the common staging approach used to risk-stratify patients with NDMM and has been validated in several studies. Staging is based on the amount of albumin, beta-2-microglobulin, and lactate dehydrogenase (LDH) in the blood, as well as specific gene abnormalities (cytogenetics) of the cancer. However, the distribution of patients in R-ISS results in the majority being classified as intermediate. Incorporating cytogenic risk factors and an improved of prognostic implications of multi-hit disease, there is a new simple additive staging system available in patients with NDMM. (22) Morbidity: The risk of second primary cancers in MM survivors (23) (24) was assessed in cancer registries of Germany and Sweden, treated mainly with Melphalan ± autologous transplant. (25) Significantly elevated Standardized Incidence Ratios were observed for: • acute myeloid leukemia (standardized incidence ratios = 4.9 and 2.3 in Germany and Sweden respectively), • kidney cancer (2.3), • nervous system cancer (1.9). However, one study from Swedish registers indicated that patients with a prior malignancy diagnosis had a significantly increased risk of developing a subsequent

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
	malignancy compared with MM patients without a prior malignancy diagnosis (HR 1.42, 95% confidence interval [CI]: 1.23-1.65). (26) In a most recent study, among 737 patients with NDMM not eligible for ASCT and randomly assigned to daratumumab plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, respectively 8.8% and 7.1% had developed a SPM after a 28-month follow-up and 20% and 13% after 56 months of follow-up. (23) (24) Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide. (27) Drugs as Melphalan, as well as autologous transplant are less/not part of treatment strategy for MM patients not eligible for transplant. The profile of SPM will evolve with time and use of different drugs like immunomodulatory agents in front line setting. Infection is a significant cause of morbidity and the leading cause of death in patients with myeloma. The risk depends on the remission status of the underlying disease, type of therapy applied, extent of prior therapy, and presence of co-morbidities and organ dysfunctions and therefore, no estimate may be provided. (28) Mortality: Newly diagnosed multiple myeloma risk of early mortality: A study conducted in Asia involving patients with NDMM (N = 460) identified that being male, having primary PCL, plasma cells of bone marrow 60%, hemoglobin <10.0 g/dL, platelets <150 000/mL, low serum albumin (<3.5 g/dL), corrected serum calcium 12 mg/dL, serum creatinine 2 mg/dL, LDH 250 U/L, serum beta-2 microglobulin (b2M) 5500 mg/L, and ECOG 2 were significant predictors for early mortality in patients with MM. Infection was identified as the direct cause of early death in the majority of patients. (29) Multiple Myeloma: Despite the increase in incidence over the past decades in the US, mortality from MM has fallen due to the drastic increase in survival. In other words, a 2.27 increase in 5-year survival over the past decades, from 23.7% in 1976 to 53.9% in 2016. The current mortality of MM in the US (3.3/100 000) is 18% below the peak of 4.0/100 000 in 1994. Approximately 12 800 people were estimated to pass away in 2020 from MM, accounting for 2.1% of all cancer deaths. According to the surveillance epidemiology and end results (SEER) program, the overall mortality rate has dropped for all ages from 3.3/100 000 in 2013 to 3.2/10 000 in 2017, and in the greater than 65 age groups from 21.7/100 000 in 2013 to 20.5/100 000 in 2017. (9) Mortality from MM globally has risen by 94% from 1990 to 2016. In 2018, an estimated 106 000 people globally perished of MM, accounting for 1.1% of all cancer deaths. Approximately, 59 000 of those deaths were male and 47 000 were female, equaling an age-standardized mortality of 1.3/100 000 and 0.9/100 000, respectively. The median age of death is 75 with approximately 80% of deaths occurring in patients over the age of 65. (9) The European Cancer Observatory (ECO) reports an age-standardized (European population) mortality rate of 2.5/100 000.

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant
	The risk of death from MM (GLOBOCAN 2018) was 0.15% among men and 0.10% among women, which was similar to the sex discrepancies in cancer risk and indicated a similar survival between sexes from global estimates. (9) A German population-based study published in 2023 reported the following causes of death (displayed by International Classification of Diseases [ICD]-10 chapter) in patients with MM: • Multiple myeloma and plasma cell neoplasms (C90) 76.8% • Cardiovascular diseases (I00-I99) 7.0% • Non-myeloma malignancies (C00-D48, excluding C90) 6.1% • Respiratory diseases (J00-J99) 1.9% • Diseases of the genitourinary system (N00-N99) 1.1% • Certain infectious and parasitic diseases (A00-B99) 1.0% • Endocrine, nutritional and metabolic diseases (E00-E90) 0.8% • Gastrointestinal diseases (K00-K93) 0.8% • Mental and behavioral disorders (F00-F99) 0.3% • Diseases of the nervous system and sensory organs (G00-H95) 0.3% • Non-informative causes of death (R00-R94, R95-R99) 1.1% • Unknown 1.5%. Survival: The overall survival in patients with MM has greatly improved over the last two decades, especially with the broader use of novel drugs and autologous tandem transplantation. (29) The most recent 10-year survival figures are in the range of 20% (Swedish Registry) to 32.6% (German registries) with substantial differences across age groups. (30) (31) In France, the 5-year and 10-year survival reported over 2005-2010 were 47% and 27% respectively. There is a substantial age effect with a 5-year survival of 75% in 15-55 years old, 43% in 65-75 years old and 23% in 75 years old and more. (32)
Important co-morbidities	The most frequent co-morbidity is renal disease (OR 11.0, 95% CI: 8.1-14.9), based on a Danish nationwide population-based study. (33) In a Swedish nationwide study investigating the burden of comorbidities on patients diagnosed with MM over a 23-year period, patient survival from the Swedish Cancer Registry was investigated. Over half of the population (54% of 13 656 patients) had evidence of at least one comorbidity at diagnosis. Of those patients, 55.7% were male and 44.3% were female, and the patients with a known comorbidity were generally older. Of all MM patients (N = 13 656), 24.6% had only one comorbidity listed at the MM diagnosis, 14.1% had two comorbidities, and 15.6% had three or more comorbidities at diagnosis. Of all MM patients under study, the most common comorbidities were the following (34): • Hypertension (20.4%) • Cancer (11.3%) • Arrhythmia (11.3%) • Chronic ischemic heart disease (9.2%) • Heart failure (9.2%) • Diabetes mellitus (8.4%) • Cerebrovascular disease (7.7%)

Indication	Multiple Myeloma including relapsed, refractory and, newly diagnosed ineligible for autologous stem cell transplant																																																
	- Psychological disease (6.1%) - Chronic lung disease (6.0%) Based on a systematic literature search and random-effects meta-analysis over 34 studies (N = 3023) the most prevalent symptoms are (35): - Fatigue (98.8%, 95% CI: 98.1-99.2%); - Pain (73%, 39.9-91.7); - Constipation (65.2%, 22.9-92.2); - Tingling in the hands/feet (neuropathy) (53.4%, 0.4-99.7). In Newly diagnosed MM patients not eligible to Stem Cell Transplant (NDMM-TI) The following table displays main comorbidities (13) of 17 731 US NDMM patients aged 45 years and older identified in electronic health record (Medicare and Optum) who did not receive an autologous stem cell transplantation and received at least one line of treatment between 2007 and 2018, and of 178 NDMM aged 65 years or older, considered not eligible to ASCT by the treating physician and who were initiated with either a daratumumab (DRd) or a bortezomib (VRd) triplet combination (TAURUS Chart review (14). <table><tr><th></th><th>US HER (N = 17 731)</th><th colspan="2">TAURUS</th></tr><tr><th></th><th></th><th>DRd (N = 99)</th><th>VRd (N = 79)</th></tr><tr><td>Mean Charlson comorbidity Index (SD)</td><td>1.9 (2.3)</td><td>1.1 (1.4)</td><td>1.4 (1.4)</td></tr><tr><td>Hypertension</td><td>59.9%</td><td>71.7%</td><td>79.7%</td></tr><tr><td>Renal failure</td><td>30.5%</td><td>24.2%</td><td>26.2%</td></tr><tr><td>Diabetes</td><td>25.4%</td><td>16.2%</td><td>25.3%</td></tr><tr><td>Cardiac arrhythmia</td><td>23.1%</td><td>Not available</td><td>Not available</td></tr><tr><td>Chronic pulmonary disorders</td><td>18.5%</td><td>7.1%</td><td>13.9%</td></tr><tr><td>Congestive heart failure</td><td>16.7%</td><td>5.1%</td><td>6.3%</td></tr><tr><td>Hypothyroidism</td><td>14.9%</td><td>Not available</td><td>Not available</td></tr><tr><td>Valvular disease</td><td>12.8%</td><td>Not available</td><td>Not available</td></tr><tr><td>Peripheral neuropathy</td><td>11.2%</td><td>14.1%</td><td>11.4%</td></tr></table> DRd: Daratumumab/Lenalidomide/Low-dose Dexamethasone; HER: Health Electronic Records; N: Number of patients; NDMM-TI: Newly Diagnosed Multiple Myeloma patients not eligible to Stem Cell Transplant; SD: Standard Deviation; US: United States; VRd: Bortezomib/Lenalidomide/Dexamethasone. A review article examined the disease characteristics and demographics of patients with relapsed MM, focusing predominantly on those who have relapsed early in their treatment course (ie, after 1-3 prior lines of treatment) and who were enrolled in phase II or III interventional trials or observational studies (36): - Peripheral neuropathy is a common occurrence in patients with relapsed MM, resulting from complications of the disease and treatment related toxicities. Based on exclusion rate from clinical trials, the prevalence ranges from 36% to 83%. (36)		US HER (N = 17 731)	TAURUS				DRd (N = 99)	VRd (N = 79)	Mean Charlson comorbidity Index (SD)	1.9 (2.3)	1.1 (1.4)	1.4 (1.4)	Hypertension	59.9%	71.7%	79.7%	Renal failure	30.5%	24.2%	26.2%	Diabetes	25.4%	16.2%	25.3%	Cardiac arrhythmia	23.1%	Not available	Not available	Chronic pulmonary disorders	18.5%	7.1%	13.9%	Congestive heart failure	16.7%	5.1%	6.3%	Hypothyroidism	14.9%	Not available	Not available	Valvular disease	12.8%	Not available	Not available	Peripheral neuropathy	11.2%	14.1%	11.4%
	US HER (N = 17 731)	TAURUS																																															
		DRd (N = 99)	VRd (N = 79)																																														
Mean Charlson comorbidity Index (SD)	1.9 (2.3)	1.1 (1.4)	1.4 (1.4)																																														
Hypertension	59.9%	71.7%	79.7%																																														
Renal failure	30.5%	24.2%	26.2%																																														
Diabetes	25.4%	16.2%	25.3%																																														
Cardiac arrhythmia	23.1%	Not available	Not available																																														
Chronic pulmonary disorders	18.5%	7.1%	13.9%																																														
Congestive heart failure	16.7%	5.1%	6.3%																																														
Hypothyroidism	14.9%	Not available	Not available																																														
Valvular disease	12.8%	Not available	Not available																																														
Peripheral neuropathy	11.2%	14.1%	11.4%																																														

ASCT: Autologous Stem Cell Transplant; ASIR: Age-Standardized Incidence Rate; b2M: Beta-2 microglobulin; CAR T: Chimeric Antigen Receptor T-cell; CI: Confidence Interval; DaraKd: Daratumumab/Carfilzomib/ Dexamethasone; DaraPd: Daratumumab/Pomalidomide/Dexamethasone; DaraRd: Daratumumab/Lenalidomide/Dexamethasone;

DaraVd: Daratumumab/Bortezomib/Dexamethasone; DaraVMP: Daratumumab/Bortezomib/Melphalan/Prednisone;
DaraVTD: Daratumumab/Bortezomib/Thalidomide/Dexamethasone; DRd: Daratumumab/Lenalidomide/Low-dose Dexamethasone;
ECO: European Cancer Observatory; ECOG: Eastern Cooperative Oncology Group; EloRd: Elotuzumab/Lenalidomide/Dexamethasone;
ESMO: European Society for Medical Oncology; EU: European Union; GLOBOCAN: Global Cancer Observatory; HER: Health Electronic
Records; HR: Hazard Ratio; IARC: International Agency for Research on Cancer; ICD: International Classification of Diseases;
IMiDs: Immunomodulatory Agents; IRd: Ixaxomib/Lenalidomide/Low-dose Dexamethasone; Isa-Kd: Isatuximab/Carfilzomib/Dexamethasone;
Isa-Pd: Isatuximab/Pomalidomide/Dexamethasone; Kd: Carfilzomib/ Dexamethasone; KRd: Carfilzomib/Lenalidomide/Dexamethasone;
LDH: Lactate Dehydrogenase; N: Number; MABs: Monoclonal Antibodies; MM: Multiple Myeloma; NCCN: National Comprehensive Cancer
Network; NDMM: Newly Diagnosed Multiple Myeloma; NDMM-T1: Newly diagnosed Multiple Myeloma patients not eligible to Stem Cell
Transplant; NE: Not Estimable; PomVd: Pomalidomide/Bortezomib/Dexamethasone; OR: Odds Ratio; OS: Overall Survival;
PCd: Pomalidomide/Cyclophosphamide/Dexamethasone; PCL: Plasma Cell Leukemia; Pd: Pomalidomide/Dexamethasone; PFS: Progression
Free Survival; PI: Proteasome Inhibitor; RCT: Randomized Clinical Trials; Rd: Lenalidomide/Dexamethasone;
Rd-Elo: Elotuzumab/Lenalidomide/Low-dose Dexamethasone; R-ISS: Revised International Staging System; Sd: Selinexor/Dexamethasone;
SEER: Surveillance Epidemiology and End Results; SPM: Second Primary Malignancy; SVD: Selinexor/Bortezomib/Dexamethasone;
UI: Uncertainty Interval; UK: United Kingdom; US: United States; VCD: Bortezomib/Cyclophosphamide/Dexamethasone;
VenVd: Venetoclax/Bortezomib/Dexamethasone; VMP: Bortezomib/Melphalan/Prednisone; VRd: Bortezomib/Lenalidomide/Dexamethasone;
VTD: Bortezomib/Thalidomide/Dexamethasone; Vd-Pano: Panobinostat/Bortezomib/Dexamethasone.

PART II: MODULE SII - NON-CLINICAL PART OF THE SAFETY SPECIFICATION

Isatuximab is specific for the human CD 38 protein. Consequently, in the absence of a relevant animal species for toxicity testing or a relevant surrogate antibody, the overall non-clinical safety evaluation of isatuximab was limited to a repeat-dose IV (once weekly for 3 weeks) toxicity study in cynomolgus monkeys (preceded by a small exploratory study) in order to evaluate potential non-targeted and non-specific general toxicity. Local tolerance studies in rabbits and minipigs, and an in vitro compatibility study with human whole blood and plasma were also conducted.

In the repeat-dose (once weekly for 3 weeks) IV toxicity study conducted in cynomolgus monkeys (a non-pharmacologically-reactive species), isatuximab in its clinical formulation (cell 1, process 2, formulation 2 [C1P2F2]) did not produce compound-related changes in any parameters evaluated and the no observed adverse effect level (NOAEL) was 100 mg/kg/week (highest dose tested).

Even if the cynomolgus monkey is not a pharmacologically reactive species, some safety pharmacology endpoints were evaluated in the weekly repeat-dose Good Laboratory Practice (GLP) IV toxicity study conducted with isatuximab in this animal species. No isatuximab-related effects were noted in this study on electrocardiogram (ECG) parameters, blood pressure, gross behavior profile (including body temperature) and respiratory function up to the highest dose tested of 100 mg/kg/week.

The local tolerance evaluation of isatuximab in its clinical IV formulation (cell 1, process 1, formulation 1 [C1P1F1]) in rabbits (a non-pharmacologically-reactive species) demonstrated that isatuximab was well tolerated after IV injections, the intended route of administration for clinical use, as well as after intramuscular, intra-arterial, SC or paravenous injections (non-intended routes that might occur accidentally) up to 5 mg/mL (the maximum concentration tested). In addition, in cynomolgus monkeys, isatuximab in its clinical formulation (C1P2F2) did not produce compound-related macroscopic or microscopic changes at the injection sites following once weekly IV infusion for 3 weeks up to 20 mg/mL (the maximum concentration tested). Finally, the local tolerance of isatuximab SC in its clinical SC formulation has been tested in female minipigs (a non-pharmacologically relevant species). The single SC injection of 12.9 mL isatuximab (140 mg/mL, SC formulation) to minipigs equivalent to a total dose of 1806 mg/minipig at flow rates of 0.5, 1, and 2 mL/min was overall clinically well tolerated. Erythema and hemorrhage at SC injection sites were noted on the day of infusion, only, and were similar for the 3 SC flow rates as well as for isatuximab and saline. Swelling (bleb formation) at SC injection sites was more evident for isatuximab infused at 1 and 2 mL/min compared to 0.5 mL/min and was considered related to a physical phenomenon (large volume injected in a short period of time at a single site). It declined at 4 hours and had disappeared at 24 hours following administration. There were no compound-related microscopic findings at the examination of skin biopsies of SC injection sites sampled 7 and 28 days following each injection.

Isatuximab prepared in its clinical IV formulation (C1P1F1) did not induce hemolysis of human whole blood cells and was found to be compatible with human plasma up to a final concentration in blood or plasma of 2.5 mg/mL (the maximum concentration tested).

In addition, various in vitro studies were conducted to characterize the presence of CD38 on human blood cells and evaluate the in vitro biological effects of isatuximab on several types of human

blood cells, including the potential effects of isatuximab on cytokine release. Overall, no significant cytokine release, cellular activation, or depletion was induced by isatuximab in in vitro assays with normal human peripheral blood mononuclear cells, despite some induction of apoptosis in purified natural killer (NK) cells.

Based on a literature review on CD38^{-/-} mice, main side effects noted in these knockout animals included deficiencies in humoral immune responses (37), impaired glucose tolerance and reduced serum insulin level (38), reduced bone mineralization (39), deficits in learning and memory (40), impaired maternal nurturing behavior postpartum under stressful condition and impaired male social recognition. (41) However, data obtained in these genetically modified animals are only indicative of potential adverse effects and should be considered with caution. (42)

Target organs identification for potential toxicity in human could not be performed due to the lack of relevant animal species for isatuximab testing as well as lack of relevant animal surrogate antibody. Therefore, the identification of target organs for potential toxicity of isatuximab in humans is based on in vitro studies using human tissues. The GLP tissue cross-reactivity study using normal human tissues demonstrated isatuximab specific binding in the lymphoid tissues (spleen, thymus, lymph node, and tonsil) and in the bone marrow as expected, and in the pituitary gland (endothelial cells) and prostate gland (glandular epithelial cells). In addition, specific isatuximab binding was detected in infiltrating or resident round cells (macrophages and/or lymphocytes) in most tissues, including Kupffer's cells in the liver. In a previous non-GLP tissue cross-reactivity study using a different batch of isatuximab, additional staining was observed in the brain (astrocytes) and the lung (bronchial epithelium), but this was not reproduced in the GLP study. Staining of non-lymphoid tissue elements (prostate, pituitary gland, lung, and brain) was interpreted as evidence of cross-reactivity that may possibly indicate potential unintended target sites.

The presence of specific staining in some non-lymphoid human tissue elements as described above resulted, as a precautionary measure, in the implementation of systematic monitoring of the safety profile of isatuximab including the evaluation of prostate, pituitary and respiratory function before each infusion in the first-in-human Phase 1 single agent trial (TED10893) via the dosage of prostate specific antigen (PSA) levels, pituitary hormones levels (growth hormone [GH], follicle stimulating hormone [FSH]/luteinizing hormone [LH], adrenocorticotrophic hormone [ACTH], thyroid stimulating hormone [TSH]) and the implementation of pulmonary function tests (Spirometry, Diffusion Capacity) and chest X-rays. Regarding the staining noted in the brain, no specific monitoring was conducted in patients, because isatuximab is unlikely to penetrate the blood-brain barrier (BBB) to any significant degree based on its large molecular size (molecular weight: about 150 000 Da) and the restrictive nature of the BBB.

No relevant laboratory abnormalities to the above listed tests and no adverse events (AEs) were reported suggesting an effect of the study treatment on these organs/functions. Therefore, those systematic laboratory assessments during study treatment were not considered necessary in the subsequent clinical studies.

The key non-clinical findings are presented in the following table:

Table 7 - Key safety findings from non-clinical studies and relevance to human usage

Key Safety Findings	Relevance to human usage
Toxicity • Key issues identified from Acute or repeat-dose toxicity studies No relevant animal species for isatuximab toxicity testing or relevant surrogate antibody were available. In a repeat-dose (once weekly for 3 weeks) IV toxicity study conducted in cynomolgus monkeys (a non-pharmacologically-reactive species), isatuximab in its clinical formulation did not produce compound-related changes in any parameters evaluated and the NOAEL was 100 mg/kg/week (highest dose tested). • Reproductive/developmental toxicity studies As isatuximab is a biologic agent intended for the treatment of late-stage cancer patients, reproductive and developmental toxicity studies are generally not warranted with the exception of an embryofetal toxicology assessment. In the case of isatuximab and in the absence of a relevant animal species for non-clinical safety evaluation, no embryofetal toxicity studies were conducted. • Genotoxicity Monoclonal antibodies, such as isatuximab, are not expected to interact directly with DNA or other chromosomal material. Therefore, no genotoxicity studies were performed with isatuximab. • Carcinogenicity As isatuximab is a biologic agent intended for the treatment of late-stage cancer patients, carcinogenicity studies were not conducted.	Not relevant. Because of the absence of reproductive toxicity studies and clinical experience with the use of isatuximab in pregnant or women of childbearing potential not taking effective contraception, appropriate caution for use in the patients of reproductive ability is stated in the SmPC. Not relevant: it is not expected that biotechnology-derived pharmaceuticals would interact directly with DNA or other chromosomal material (ICH S6 R1) and no genotoxic effects are expected in humans. Second Primary Malignancies are considered AEs of special interest in the clinical studies of isatuximab administered in oncologic indications.
Immunogenicity Some ADAs were noted in monkeys with a batch of isatuximab beyond current shelf-life.	Immunogenicity following administration of human proteins in monkeys is known to be a poor predictor of similar responses in humans. Immunogenicity is a known class effect observed with other monoclonal antibodies, but risk of immunogenicity was expected to be low with isatuximab since isatuximab is a naked IgG1 antibody. No signal for autoimmune disorder has been identified during the clinical trials. No positive ADA samples were identified in the 151 evaluable patients during the on-treatment period for ICARIA (EFC14335) study, nor in the 168 evaluable patients during the on-treatment period for IKEMA (EFC15246) study, the incidence of ADA positive was 9.1% in 275 patients for IMROZ (EFC12522) study (global + Chinese expansion). In addition, among those with treatment-induced ADA, 15 had a neutralizing response resulting in an NAB incidence of 5.5%. Among the 383 patients with NDMM treated with isatuximab in combination with VRd and evaluable for ADA (with at least one treatment sample), the ADA incidence range from 9.1% to 21.6%, depending on the study.

Key Safety Findings	Relevance to human usage
	Although the ADA incidence is higher in NDMM patients compared to RRMM patients (<2%, N = 1023), the ADA + kinetics in NDMM patients exhibited the same pattern than those in RRMM patients: Most of the response were transient with only 1 out of the 45 treatment-induced ADA positive patients showing persistent ADA kinetics and 3 patients with indeterminate ADA response with a median onset of 0.7 to 1 month. While no impact on PK was noted in the RRMM patients, a trend to lower exposure was observed in patients with ADA + across studies (ie $\leq 30\%$ for AUC4W and CT4W in IMROZ). However, this impact of ADA was considered not clinically meaningful as no impact on safety and efficacy was evidenced. To conclude, a higher incidence of ADA + associated with an early onset observed in NDMM patients is likely attributed to a more immunocompetent status in NDMM patients compared to RRMM patients. As isatuximab is targeting B-cells that express CD38 and also produce ADA, these factors, together, explain the transient nature of ADA kinetics in both MM populations. Despite a trend to lower exposure in NDMM patients with ADA positive, no evidence of an impact of ADA could be demonstrated on safety and efficacy when isatuximab is given in combination with VRd. IRAKLIA: The incidence of treatment-emergent ADA was low (4.9%) in RRMM patients following SC administration of isatuximab and comparable to IV administration in RRMM patients. The incidence of treatment-emergent ADA was higher in the Isa-SC NDMM studies (15.9%), which is consistent with the Isa-IV NDMM studies EFC12522 (9.1%), TCD13983 (16.9%), and IIT15403 (21.6%). The incidence of treatment-emergent NABs was 0.5% and 2.3% among RRMM and NDMM patients, respectively. Regardless of the route of isatuximab administration (IV or SC), a higher incidence of ADA+ associated with an early onset was observed in NDMM patients and is likely attributed to a more immunocompetent status in NDMM patients compared to RRMM patients. As isatuximab is targeting plasma cells that express CD38 and also produce ADA, these factors, together, explain the transient nature of ADA kinetics in both MM populations. Consistently in the Isa-SC and the Isa-IV studies, ADA positivity was transient, with no evident effect on PK, safety, or efficacy. Overall, there is no increase of the incidence of ADA after SC compared to IV administration, and the immunogenicity profile of isatuximab remains the same regardless of the route of administration (SC or IV). There was no impact of ADA on isatuximab PK. No evidence of an impact of ADA could be

Key Safety Findings	Relevance to human usage
	demonstrated on safety and efficacy when isatuximab is given in combination
Safety pharmacology Even if the cynomolgus monkey is not a pharmacologically-reactive species, some safety pharmacology endpoints were evaluated in the weekly repeat-dose GLP IV toxicity study conducted with isatuximab in this animal species. No isatuximab-related effects were noted in this study on ECG parameters, blood pressure, gross behavior profile (including body temperature) and respiratory function up to the highest dose tested of 100 mg/kg/week.	Isatuximab is not likely to cross the BBB, there is no clinical evidence of CNS effects and the potential for intentional misuse for illegal purpose is considered minimal (see [Part II Module SVI]). In addition, there were no preclinical findings on vital signs that would appear to have relevance to humans. No clinically meaningful changes of ECG parameters, blood pressure, body temperature, and respiratory function were observed from the analysis of the results of the randomized, controlled, Phase III studies EFC15246 (IKEMA), EFC14335 (ICARIA)EFC12522 (IMROZ) or EFC 15951 (IRAKLIA).
Other toxicity-related information or data In vitro tissue cross reactivity studies with normal human tissues Isatuximab staining of the lymphoid tissues (spleen, thymus, lymph node, and tonsil) and in the bone marrow was expected. Staining of non-lymphoid tissue elements such as prostate, pituitary gland, lung and brain was interpreted as evidence of cross-reactivity that may possibly indicate potential unintended target sites.	The presence of specific staining in some non-lymphoid human tissue elements resulted, as a precautionary measure, in the implementation of systematic monitoring of the safety profile of isatuximab including the evaluation of prostate, pituitary and respiratory function before each infusion in the first-in-human Phase 1 single agent trial (TED10893) by monitoring PSA levels, pituitary hormones levels (GH, FSH/LH, ACTH, TSH) and implementing pulmonary function tests (Spirometry, Diffusion Capacity) and chest X-rays. Regarding the staining noted in the brain, no specific monitoring was conducted in patients, because isatuximab is unlikely to penetrate the BBB to any significant degree based on its large molecular size (molecular weight: about 150 000 Da) and the restrictive nature of the BBB. Staining of astrocytes in the brain and bronchial epithelium cells in the lungs, however, was not observed in the definitive GLP tissue cross-reactivity study. Furthermore, among the 89 patients treated in Study TED10893 Phase 1, laboratory abnormalities and AEs did not suggest evidence of an effect of the study treatment on these organ functions. Therefore, systematic laboratory assessments during study treatment have no longer been considered necessary in the subsequent clinical studies. Within the clinical trials experience with isatuximab, PSA and pituitary hormones were evaluated in Study TED10893 Phase 1. Fluctuations in the median values were observed in all treatment dose groups; the median of the last on-treatment value, however, was similar to the baseline. These fluctuations do not correspond to AEs suggesting no effect of the treatment on these organ functions. There was an increase in the incidence of dyspnea, all grade and grade ≥ 3 in both EFC14335 (ICARIA) and EFC15246 (IKEMA) studies, but these were mostly due to either pre-existing respiratory conditions, treatment emergent respiratory infections, or disease progression and

Key Safety Findings	Relevance to human usage
	dyspnea was therefore not considered an important independent risk. In study EFC12522 (IMROZ), there were less cases of dyspnea in the IVRd arm than in the VRD arm. In study EFC 15951 (IRAKLIA), the cases of dyspnea were similar in the Isa-SC +Pd arm compared to the Isa-IV + Pd arm. Respiratory infections, as stated above, are known to occur with CD38 antibody treatment and are well managed with dose reductions, colony stimulating factors and anti-infective agents as needed. In these two trials, no AEs of the pituitary or prostate were observed that suggested an effect of the treatment on these organ functions.
Literature review on CD38 knockout mice Main side effects noted in these CD38^{-/-} animals included deficiencies in humoral immune responses, impaired glucose tolerance and reduced serum insulin level, reduced bone mineralization, deficits in learning and memory, impaired maternal nurturing behavior postpartum under stressful condition and impaired male social recognition.	Data obtained in genetically modified animals such as knockout mice are only indicative of potential effects and should be considered with caution because potential secondary and parallel effects from genetic manipulations may confound results. Knockout mice may have uncharacterized compensatory mechanisms or redundant pathways that are not readily apparent to replace the function of the absent protein or target. Finally, knockout mice that lack a target throughout embryogenesis and development may not accurately reflect the clinical scenario where the protein function may be nullified only during adulthood. Therefore, their use in assessing safety is more supportive rather than providing definitive safety data.

ACTH: Adrenocorticotrophic Hormone; ADA: Anti-Drug Antibody; AE: Adverse Event; BBB: Blood Brain Barrier; CD: Cluster of Differentiation; CNS: Central Nervous System; DNA: Deoxyribonucleic Acid; ECG: Electrocardiogram; FSH: Follicle Stimulating Hormone; GH: Growth Hormone; GLP: Good Laboratory Practice; ICH: International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use; IgG: Immunoglobulin G; Isa-Pd: Isatuximab/Pomalidomide/Dexamethasone; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; LH: Luteinizing Hormone; MM: Multiple Myeloma; N: Number; NAb: Neutralizing Antibody; NDMM: Newly Diagnosed Multiple Myeloma; NOAEL: No Observed Adverse Effect Level; PK: Pharmacokinetic; PSA: Prostate Specific Antigen; RRMM: Relapsed Refractory Multiple Myeloma; SC: Subcutaneous; SmPC: Summary of Product Characteristics; TSH: Thyroid Stimulating Hormone; VRd: Bortezomib/Lenalidomide/Dexamethasone.

No additional non-clinical data have been collected on the use of isatuximab in any special populations.

PART II: MODULE SIII - CLINICAL TRIAL EXPOSURE

The clinical development program for isatuximab includes clinical trials to develop an IV formulation (isatuximab 100 mg/5mL concentrate for solution for infusion) and clinical trials to develop a SC formulation (isatuximab 1400 mg solution for injection).

Intravenous formulation:

The analysis of safety data for the already approved indications, were based on the following presentation strategies:

- **ICARIA:** Indication 1 in [Table 8](#) to [Table 14](#) below: At the time of the dossier cut-off date (15 November 2018), the following 6 company-sponsored studies had been completed and their data were integrated in a common safety database: the pivotal Phase 3 MM trial (EFC14335) and 5 supportive studies (TCD14079 Part A, TED10893, TED14154 Part A, TCD11863, TCD13983 ICBd).
- **IKEMA:** Indication in [Table 8](#) to [Table 14](#) below: At the time of the dossier cut-off date (07 February 2020), the following sponsored studies had been completed and their data were integrated in a common safety database: the pivotal Phase 3 MM trials (EFC15246 and FC14335) and supportive studies (TCD14079, TED10893, TED14095, TED14154, TCD11863, TCD13983 and TCD14906).
- **IMROZ** (Indication 3 and **GMMG-HD7** (Indication 4) in [Table 8](#) to [Table 14](#) below. The analysis of safety data for the extension of indication in NDMM patients, were based on the following presentation strategy:
 - Isa-VRD in patients with NDMM not eligible for transplant (Study EFC12522/IMROZ) global portion, and in patients with NDMM eligible for autologous stem cell transplant (Studies GMMG HD7 and TCD13983).
 - All-Isa pool. The All-Isa pool aims to provide pooled safety data for NDMM patients (from Studies EFC12522/IMROZ, IIT15403/GMMG HD7 and TCD13983). This is further supplemented with comprehensive safety data from all studies in which patients were exposed to isatuximab including those with NDMM and RRMM.

Subcutaneous formulation:

Data supporting isatuximab SC in subjects with MM are based on the following presentation strategy.

- **Isa-SC + Pd** in RRMM patients (from studies EFC15951 [IRAKLIA] and TCD15484),
- **Isa-SC+Kd** in RRMM patients (from study ACT17453 [IZALCO]),
- **Isa-SC+VRd** in NDMM patients (from studies IIT17756 [IFM2022-05 - ISASOCUT] and study IIT17041 [GMMG-HD8 / DSMM XIX]).
- **All Isa-SC.** The All-Isa-SC pool aims to provide pooled safety data for RRMM and NDMM patients.

Tables of exposure – IV formulation

Table 8 - Duration of exposure – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	IkD (N = 177) (Indication 2)	IPd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Number of patients treated by isatuximab	692	177	244	498	1787
Duration of exposure (n [%])					
At least 1 month	669 (96.7)	172 (97.2)	230 (94.3)	423 (84.9)	1656 (92.7)
At least 3 months	652 (94.2)	163 (92.1)	196 (80.3)	266 (53.4)	1395 (78.1)
At least 6 months	338 (48.8)	148 (83.6)	157 (64.3)	164 (32.9)	888 (49.7)
At least 9 months	313 (45.2)	134 (75.7)	131 (53.7)	110 (22.1)	746 (41.7)
At least 12 months	296 (42.8)	124 (70.1)	110 (45.1)	75 (15.1)	649 (36.3)
At least 15 months	283 (40.9)	110 (62.1)	97 (39.8)	46 (9.2)	572 (32.0)
At least 18 months	269 (38.9)	101 (57.1)	83 (34.0)	18 (3.6)	499 (27.9)
At least 21 months	264 (38.2)	90 (50.8)	70 (28.7)	13 (2.6)	461 (25.8)
At least 24 months	259 (37.4)	81 (45.8)	63 (25.8)	8 (1.6)	433 (24.2)
>24 months	259 (37.4)	81 (45.8)	63 (25.8)	8 (1.6)	433 (24.2)

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq$ 1.5 $\times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST >ULN, Moderate: 1.5 $\times$ ULN < Total Bilirubin $\leq$ 3 $\times$ ULN and AST = Any, Severe: Total Bilirubin >3 $\times$ ULN and AST = Any. Renal status (eGFR: Estimated Glomerular Filtration Rate, mL/min/1.73m²) is defined as follows, Normal: $\geq$ 90, Mild: $\geq$ 60 to <90, Moderate: $\geq$ 30 to <60, Severe: $\geq$ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35)

Note: Percentages are calculated using the number of patients treated as denominator.

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone;

Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 9 - Exposure by age group and gender – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	lkd (N = 177) (Indication 2)	lpd (N = 244) (Indication 1)	lsa (±Dex) (N = 498)	All (N = 1787)
Number of patients treated by isatuximab	692	177	244	498	1787
Gender [n(%)]					
Male	390 (56.4)	99 (55.9)	145 (59.4)	265 (53.2)	993 (55.6)
Female	302 (43.6)	78 (44.1)	99 (40.6)	233 (46.8)	794 (44.4)
Age group (years) [n(%)]					
<65	281 (40.6)	87 (49.2)	95 (38.9)	224 (45.0)	763 (42.7)
65-74	326 (47.1)	74 (41.8)	103 (42.2)	193 (38.8)	772 (43.2)
75-84	83 (12.0)	15 (8.5)	44 (18.0)	78 (15.7)	243 (13.6)
≥85	2 (0.3)	1 (0.6)	2 (0.8)	3 (0.6)	9 (0.5)

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN < Total Bilirubin ≤ 1.5 × ULN and AST = Any or Total Bilirubin ≤ ULN and AST > ULN, Moderate: 1.5 × ULN < Total Bilirubin ≤ 3 × ULN and AST = Any, Severe: Total Bilirubin > 3 × ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; lkd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; lpd: Isatuximab in combination with Pomalidomide and Dexamethasone; lsa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 10 - Exposure by age group and gender (person-years) – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	lkd (N = 177) (Indication 2)	lpd (N = 244) (Indication 1)	lsa (±Dex) (N = 498)	All (N = 1787)
Isatuximab exposure (person-years)	1314.0	399.7	344.6	240.3	2474.7
Gender (person-years)					
Male	706.6	225.6	204.1	132.7	1355.9
Female	607.4	174.1	140.5	107.6	1118.7
Age group (years) (person-years)					
<65	168.4	195.1	136.6	96.1	639.5
65-74	878.3	176.2	154.1	91.1	1420.3
75-84	262.9	27.9	53.2	51.9	407.8
≥85	4.3	0.6	0.7	1.2	7.1

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	lkd (N = 177) (Indication 2)	lpd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq 1.5 \times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST > ULN, Moderate: $1.5 \times$ ULN < Total Bilirubin $\leq 3 \times$ ULN and AST = Any, Severe: Total Bilirubin $> 3 \times$ ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90 , Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_p1_s_t_i.rtf (14FEB2024 9:36)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; lkd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; lpd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 11 - Exposure by ethnic origin – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	lkd (N = 177) (Indication 2)	lpd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Number of patients treated by isatuximab	692	177	244	498	1787
Ethnicity [n(%)]					
Hispanic or Latino	4 (0.6)	12 (6.8)	12 (4.9)	36 (7.2)	76 (4.3)
Not Hispanic or Latino	249 (36.0)	142 (80.2)	209 (85.7)	347 (69.7)	1083 (60.6)
Not Reported or Unknown	439 (63.4)	23 (13.0)	23 (9.4)	115 (23.1)	628 (35.1)

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq 1.5 \times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST > ULN, Moderate: $1.5 \times$ ULN < Total Bilirubin $\leq 3 \times$ ULN and AST = Any, Severe: Total Bilirubin $> 3 \times$ ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90 , Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; lkd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; lpd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 12 - Exposure by ethnic origin (person-years) – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	lkd (N = 177) (Indication 2)	lpd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Isatuximab exposure (person-years)	1314.0	399.7	344.6	240.3	2474.7
Ethnicity (person-years)					
Hispanic or Latino	13.5	31.6	12.3	21.3	85.1

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	IkD (N = 177) (Indication 2)	IPd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Not Hispanic or Latino	818.6	316.1	312.3	178.5	1719.9
Not Reported or Unknown	481.9	52.0	20.0	40.6	669.7

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq$ 1.5 $\times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST > ULN, Moderate: 1.5 $\times$ ULN < Total Bilirubin $\leq$ 3 $\times$ ULN and AST = Any, Severe: Total Bilirubin > 3 $\times$ ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: $\geq$ 90, Mild: $\geq$ 60 to <90, Moderate: $\geq$ 30 to <60, Severe: $\geq$ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_p1_s_t_i.rtf (14FEB2024 9:36)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 13 - Exposure by race – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	IkD (N = 177) (Indication 2)	IPd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Number of patients treated by isatuximab	692	177	244	498	1787
Race [n(%)]					
White	566 (81.8)	130 (73.4)	199 (81.6)	349 (70.1)	1386 (77.6)
Black or African American	4 (0.6)	5 (2.8)	6 (2.5)	25 (5.0)	53 (3.0)
Asian	56 (8.1)	25 (14.1)	23 (9.4)	61 (12.2)	175 (9.8)
Other	9 (1.3)	3 (1.7)	2 (0.8)	21 (4.2)	36 (2.0)
Not Reported or Unknown	57 (8.2)	14 (7.9)	14 (5.7)	42 (8.4)	137 (7.7)

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq$ 1.5 $\times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST > ULN, Moderate: 1.5 $\times$ ULN < Total Bilirubin $\leq$ 3 $\times$ ULN and AST = Any, Severe: Total Bilirubin > 3 $\times$ ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: $\geq$ 90, Mild: $\geq$ 60 to <90, Moderate: $\geq$ 30 to <60, Severe: $\geq$ 15 to <30, End stage renal disease: <15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Table 14 - Exposure by race (person-years) – Cumulative and by indication (IV formulation)

	Isatuximab				
	IVRd (N = 692) (Indication 3 and 4)	IkD (N = 177) (Indication 2)	IPd (N = 244) (Indication 1)	Isa (±Dex) (N = 498)	All (N = 1787)
Isatuximab exposure (person-years)	1314.0	399.7	344.6	240.3	2474.7
Race (person-years)					
White	897.8	289.8	289.7	163.9	1797.5
Black or African American	6.7	9.2	1.7	9.8	32.6
Asian	178.9	70.3	42.1	43.1	343.4
Other	22.0	7.3	2.0	8.2	40.6
Not Reported or Unknown	208.7	23.0	9.1	15.2	260.4

Note: Percentages are calculated using the number of patients treated as denominator.

Note: Hepatic status is defined as follows, Normal: Total bilirubin $\leq$ ULN and AST $\leq$ ULN, Mild: ULN < Total Bilirubin $\leq$ 1.5 $\times$ ULN and AST = Any or Total Bilirubin $\leq$ ULN and AST > ULN, Moderate: 1.5 $\times$ ULN < Total Bilirubin $\leq$ 3 $\times$ ULN and AST = Any, Severe: Total Bilirubin > 3 $\times$ ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: $\geq$ 90, Mild: $\geq$ 60 to < 90, Moderate: $\geq$ 30 to < 60, Severe: $\geq$ 15 to < 30, End stage renal disease: < 15.

PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_p1_s_t.i.rf (14FEB2024 9:36)

AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IkD: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.

Tables of exposure - SC formulation

Table 15 - Duration of exposure - Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Number of patients treated by isatuximab	307	74	141	522
Duration of exposure (n [%])				
At least 1 month	294 (95.8)	70 (94.6)	139 (98.6)	503 (96.4)
At least 3 months	278 (90.6)	67 (90.5)	135 (95.7)	480 (92.0)
At least 6 months	210 (68.4)	57 (77.0)	73 (51.8)	340 (65.1)
At least 9 months	134 (43.6)	30 (40.5)	70 (49.6)	234 (44.8)
At least 12 months	90 (29.3)	5 (6.8)	37 (26.2)	132 (25.3)
At least 15 months	58 (18.9)	1 (1.4)	1 (0.7)	60 (11.5)
At least 18 months	37 (12.1)	0	0	37 (7.1)
At least 21 months	23 (7.5)	0	0	23 (4.4)
At least 24 months	13 (4.2)	0	0	13 (2.5)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N =141)	All Isa-SC (N = 522)
>24 months	13 (4.2)	0	0	13 (2.5)

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

Note: Percentages are calculated using the number of patients treated as denominator.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 16 - Exposure by age group and gender - Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Number of patients treated by isatuximab	307	74	141	522
Gender [n(%)]				
Male	162 (52.8)	41 (55.4)	77 (54.6)	280 (53.6)
Female	145 (47.2)	33 (44.6)	64 (45.4)	242 (46.4)
Age group (years) [n(%)]				
<65	138 (45.0)	35 (47.3)	53 (37.6)	226 (43.3)
65-74	107 (34.9)	29 (39.2)	63 (44.7)	199 (38.1)
75-84	58 (18.9)	9 (12.2)	25 (17.7)	92 (17.6)
≥85	4 (1.3)	1 (1.4)	0	5 (1.0)

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

Note: Percentages are calculated using the number of patients treated as denominator.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 17 - Exposure by age group and gender (person-years) - Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Isatuximab exposure (person-years)	256.1	48.9	95.4	400.4
Gender (person-years)				
Male	138.9	28.4	51.7	219.0
Female	117.2	20.5	43.8	181.5
Age group (years) (person-years)				
<65	110.1	24.9	18.1	153.2
65-74	97.5	17.1	54.4	169.1
75-84	45.1	6.4	22.9	74.4
≥85	3.4	0.5	0	3.9

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 18 - Exposure by ethnic origin – Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Number of patients treated by isatuximab	307	74	141	522
Ethnicity [n(%)]				
Hispanic or Latino	53 (17.3)	28 (37.8)	0	81 (15.5)
Not Hispanic or Latino	233 (75.9)	38 (51.4)	0	271 (51.9)
Not Reported or Unknown	21 (6.8)	8 (10.8)	141 (100)	170 (32.6)

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

Note: Percentages are calculated using the number of patients treated as denominator.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 19 - Exposure by ethnic origin (person-years) – Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Isatuximab exposure (person-years)	256.1	48.9	95.4	400.4
Ethnicity (person-years)				
Hispanic or Latino	40.2	20.9	0	61.1
Not Hispanic or Latino	196.8	22.7	0	219.5
Not Reported or Unknown	19.1	5.3	95.4	119.8

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 20 - Exposure by race – Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Number of patients treated by isatuximab	307	74	141	522
Race [n(%)]				
White	219 (71.3)	54 (73.0)	66 (46.8)	339 (64.9)
Black or African American	8 (2.6)	8 (10.8)	0	16 (3.1)
Asian	56 (18.2)	3 (4.1)	0	59 (11.3)
Other	4 (1.3)	5 (6.8)	1 (0.7)	10 (1.9)
Not Reported or Unknown	20 (6.5)	4 (5.4)	74 (52.5)	98 (18.8)

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

Table 21 - Exposure by race (person-years) – Cumulative and by treatment (SC formulation)

	Isatuximab			
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)
Isatuximab exposure (person-years)	256.1	48.9	95.4	400.4
Race (person-years)				
White	187.6	34.7	22.8	245.1
Black or African American	4.7	6.8	0	11.5
Asian	43.8	2.2	0	46.0
Other	1.9	3.0	0.4	5.3
Not Reported or Unknown	18.2	2.2	72.2	92.6

Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study.

PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_py_s_t.sas

OUT = REPORT/OUTPUT/cdc_isa_cat_py_s_t_x.rtf (06MAY2025 10:44)

Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma;

Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous;

VRd: Bortezomib/Lenalidomide/Dexamethasone.

PART II: MODULE SIV - POPULATIONS NOT STUDIED IN CLINICAL TRIALS

SIV.1 EXCLUSION CRITERIA IN PIVOTAL CLINICAL STUDIES WITHIN THE DEVELOPMENT PROGRAMME

Table 22 - Important exclusion criteria in pivotal studies in the development programme

Exclusion criteria	Reason for exclusion	Is it considered to be included as missing information?	Rationale (if not including as missing information)
Pregnant or breastfeeding females, or females who intend to become pregnant during the participation in a study.	To avoid potential harm to an unborn fetus or a newborn through exposure of drug from breast milk.	No	Not included as per CHMP request in initial dossier.
ICARIA (EFC14335): Patients with total bilirubin $>2 \times \text{ULN}$; AST and/or ALT $>3 \times \text{ULN}$. IKEMA (EFC15246): Patients with total bilirubin $>1.5 \times \text{ULN}$; except for known Gilbert syndrome. IMROZ (EFC12522): Total bilirubin $>1.5 \times \text{ULN}$, except for known Gilbert syndrome. AST and/or ALT $>3 \times \text{ULN}$. TCD13983: AST and/or ALT ≥ 3 times normal level and/or serum bilirubin $\geq 1.5 \times \text{ULN}$ if not due to hereditary abnormalities such as Gilbert's disease. IRAKLIA: Total bilirubin $>1.5 \times \text{ULN}$ ($>3 \times \text{ULN}$ if Gilbert syndrome). Aspartate aminotransferase and/or ALT $>3 \times \text{ULN}$.	Based on the pomalidomide label, patients with bilirubin values >2 were not enrolled in their trials. Aspartate aminotransferase and ALT >3 was already in all protocols including the single agent TED10893 as there were no data.	No	Isatuximab is not cleared via hepatic clearance and no safety concern associated with the use of isatuximab in hepatic impaired patients is anticipated.
ICARIA (EFC14335): Renal function (eGFR) $<30 \text{ mL/min/1.73 m}^2$ IKEMA (EFC15246): Renal function (eGFR) $<15 \text{ mL/min/1.73 m}^2$ IMROZ (EFC12522): Renal function eGFR $<30 \text{ mL/min/1.73 m}^2$ TCD13983: Patients with severe renal insufficiency (Creatinine Clearance $<30 \text{ mL/min}$) IRAKLIA: Estimated Glomerular Filtration Rate $<30 \text{ mL/min/1.73 m}^2$ (modification of diet in renal disease [MDRD] Formula).	Impairment of renal function is an important complication of MM, and a predictor of poor prognosis. For this reason, severe renal impairment was an exclusion criterion in study EFC14335, to ensure that the study patients had adequate renal function and to avoid confounding safety results in	No	Based on population PK analyses using data from phase 1 to phase 3 studies (N = 823patients), no dosage adjustment is necessary for patients with moderate and severe renal impairment. Approximately 33% of patients enrolled in study EFC14335 had moderate renal impairment (≥ 30 to $<60 \text{ mL/min/1.73 m}^2$) at baseline: no apparent difference in the safety profile could be observed in these patients.

Exclusion criteria	Reason for exclusion	Is it considered to be included as missing information?	Rationale (if not including as missing information)
	patients who may be requiring dialysis.		An eGFR of ≥ 30 to < 60 mL/min/1.73 m² was present at baseline in 145/263 (55.1%) the isatuximab arm of study IMROZ (EFC12522). An eGFR of < 60 mL/min/1.73 m² was present at baseline in 65/331 (19.6%) the isatuximab arm of study TCD13983. TED16414: Pharmacokinetic exposure from 22 patients with end-stage renal disease (ESRD) (eGFR < 15 mL/min/1.73 m²), were consistent with those from studies ACT15319, ACT15377, ACT15320, and TCD14906 studies (which included isatuximab in combination with cemiplimab in patients with solid tumors, lymphoma or RRMM or istuximab isatuximab monotherapy in RRMM patients) thus indicating no effect of ESRD on isatuximab PK parameters Among the 769 patients included in the population analysis using data from the 5 SC studies, 380 patients were identified with mild renal impairment (60 mL/min/1.73 m² $\leq$ eGFR < 90 mL/min/1.73 m²), 187 patients with moderate renal impairment (30 mL/min/1.73 m² $\leq$ eGFR < 60 mL/min/1.73 m²) and 7 patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²).
Significant cardiac dysfunction; myocardial infarction within 12 months; unstable, poorly controlled angina pectoris.	Patients with significant cardiac dysfunction were systematically excluded from trials with isatuximab in combination with pomalidomide, because of restrictions inherent to the use of pomalidomide.	No	The absence of safety data in this population does not constitute a safety concern.

Exclusion criteria	Reason for exclusion	Is it considered to be included as missing information?	Rationale (if not including as missing information)
IMROZ (EFC12522): Second/third degree heart block; Poorly controlled hypertension; Myocardial infarction; Severe/unstable angina pectoris; Coronary/peripheral artery bypass graft; New York Heart Association class III or IV congestive heart failure; Grade ≥ 3 arrhythmias, Stroke or transient ischemic attack. In the 6 months prior to randomization. Left-ventricular ejection fraction <40%.	Based on the warning in the lenalidomide label that myocardial infarction has been reported in patients receiving lenalidomide, particularly in those with known risk factors and within the first 12 months when used in combination with dexamethasone. In addition, these criteria ensure that in case of drug-induced cardiac complications, these effects can be detected without the interference of important confounding morbidities at baseline.		
Known Human Immunodeficiency Virus (HIV)+ status or hepatitis A, B or C active infection	These conditions interfere with CD4+ lymphocytes, weakening the immune system, and are known risk factors for infections, cancer, and mortality.	No	The absence of safety data in this population does not constitute a safety concern.
Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.	Based on the carfilzomib label, there is a warning about thrombocytopenia, hemorrhage, and thrombotic microangiopathy. Thrombocytopenia is a major dose limiting toxicity of lenalidomide and included in warnings and precautions in label, and physicians and patients are advised of increased risk of bleeding.	No	The absence of safety data in this population does not constitute a safety concern. Isatuximab safety data does not indicate an imbalance of hemorrhage or thrombotic events.

Exclusion criteria	Reason for exclusion	Is it considered to be included as missing information?	Rationale (if not including as missing information)
IMROZ (EFC12522)/ IRAKLIA (EFC 25951): Malabsorption syndrome or any condition that can significantly impact the absorption of lenalidomide or pomalidomide (as an example: hereditary problems of galactose intolerance, Lapp lactose deficiency).	To ensure that lenalidomide or pomalidomide is absorbed	No	The absence of safety data in this population does not constitute a safety concern.

ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; CD: Cluster of Differentiation; CHMP: Committee for Medicinal Products for Human Use; eGFR: Estimated Glomerular Filtration Rate; ESRD: End-Stage Renal Disease; HIV: Human Immunodeficiency Virus; MM: Multiple Myeloma; MRD: Modification of Diet in Renal Disease; PK: Pharmacokinetic; RRMM: Relapsed/Refractory Multiple Myeloma; ULN: Upper Limit of Normal.

SIV.2 LIMITATIONS TO DETECT ADVERSE REACTIONS IN CLINICAL TRIAL DEVELOPMENT PROGRAMMES

The clinical development program is unlikely to detect certain types of adverse reactions such as rare adverse reactions, adverse reactions with a long latency, or those caused by prolonged or cumulative exposure.

- Rare adverse reactions should be understood as ($\geq 1/10\,000$ to $< 1/1000$).
- Adverse reactions with a long latency: While the duration of follow-up during a clinical study is normally not sufficient to detect adverse reactions with a long latency (with a long interval between the last administration and the onset of the adverse reaction), post-treatment adverse events are systematically monitored using routine pharmacovigilance. However, the extended follow ups of the RRMM trials and the NDMM program included patients with longer exposure.

Adverse reactions caused by prolonged or cumulative exposure: The median exposure to isatuximab in the pool of isatuximab clinical studies (IV formulation) from the integrated summary of safety with data cut-off of 26 September 2023 (including RRMM and NDMM studies) was 24.36 weeks, and the maximum exposure was 299.0 weeks. A total of 27.9% (499 patients) had exposure for ≥ 18 months and 24.2% (433 patients) for > 24 months. In the All Isa-SC group (including RRMM and NDMM studies) from the integrated summary of safety ISS, the number of cycles started was 5026 cycles, median duration of overall exposure was 8.28 months (range 0.2 to 45.8), the median number of cycles started was 9.0 cycles (range 1 to 48), and 351 (67.2%) participants had at least 6 months of exposure. There is no cutoff date for inclusion of studies in the submission in the Summary of Clinical Safety (SCS) Module 2.7.4. No adverse events from cumulative drug exposure, which suggest off-target organ effects, have been observed during the clinical development program. Diseases that develop with long cumulative exposure or with long latency, such as SPMs have been observed in the clinical study program and will also be monitored using routine pharmacovigilance. Although SPMs have been observed more frequently in the isatuximab arm of several studies the exposure adjusted differences are less marked, and the rate

currently observed in the pooled database (6.0%) is below the upper end of the range of frequencies reported in multiple myeloma studies (1.7% to 6.6%).

SIV.3 LIMITATIONS IN RESPECT TO POPULATIONS TYPICALLY UNDER-REPRESENTED IN CLINICAL TRIAL DEVELOPMENT PROGRAMMES

Table 23 - Exposure of special populations included or not in clinical trial development programmes

Type of special population	Exposure																																																				
Pregnant women	Not included in the clinical development program																																																				
Breastfeeding women																																																					
Pediatric patients	Not included in the clinical development program																																																				
Elderly patients	IV formulation <table> <tr> <th></th><th colspan="5">Isatuximab</th></tr> <tr> <th></th><th>IVRd (N = 692)</th><th>IKd (N = 177)</th><th>IPd (N = 244)</th><th>Isa (±Dex) (N = 498)</th><th>All (N = 1787)</th></tr> <tr> <td>Number of patients treated by isatuximab</td><td>692</td><td>177</td><td>244</td><td>498</td><td>1787</td></tr> <tr> <td colspan="6">Age group (years) (n [%])</td></tr> <tr> <td><65</td><td>281 (40.6)</td><td>87 (49.2)</td><td>95 (38.9)</td><td>224 (45.0)</td><td>763 (42.7)</td></tr> <tr> <td>65-74</td><td>326 (47.1)</td><td>74 (41.8)</td><td>103 (42.2)</td><td>193 (38.8)</td><td>772 (43.2)</td></tr> <tr> <td>75-84</td><td>83 (12.0)</td><td>15 (8.5)</td><td>44 (18.0)</td><td>78 (15.7)</td><td>243 (13.6)</td></tr> <tr> <td>≥85</td><td>2 (0.3)</td><td>1 (0.6)</td><td>2 (0.8)</td><td>3 (0.6)</td><td>9 (0.5)</td></tr> </table> Note: Percentages are calculated using the number of patients treated as denominator. Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN < Total Bilirubin ≤ 1.5 × ULN and AST = Any or Total Bilirubin ≤ ULN and AST > ULN, Moderate: 1.5 × ULN < Total Bilirubin ≤ 3 × ULN and AST = Any, Severe: Total Bilirubin > 3 × ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15. PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35) AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal. ICARIA (EFC14335): A population PK analysis using data from Phase 1 to 3 studies from 476 patients aged 36-85 years old (14.7% of patients in the dataset were ≥75 years of age) has demonstrated no effect on isatuximab PK in this elderly population.						Isatuximab						IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 1787)	Number of patients treated by isatuximab	692	177	244	498	1787	Age group (years) (n [%])						<65	281 (40.6)	87 (49.2)	95 (38.9)	224 (45.0)	763 (42.7)	65-74	326 (47.1)	74 (41.8)	103 (42.2)	193 (38.8)	772 (43.2)	75-84	83 (12.0)	15 (8.5)	44 (18.0)	78 (15.7)	243 (13.6)	≥85	2 (0.3)	1 (0.6)	2 (0.8)	3 (0.6)	9 (0.5)
	Isatuximab																																																				
	IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 1787)																																																
Number of patients treated by isatuximab	692	177	244	498	1787																																																
Age group (years) (n [%])																																																					
<65	281 (40.6)	87 (49.2)	95 (38.9)	224 (45.0)	763 (42.7)																																																
65-74	326 (47.1)	74 (41.8)	103 (42.2)	193 (38.8)	772 (43.2)																																																
75-84	83 (12.0)	15 (8.5)	44 (18.0)	78 (15.7)	243 (13.6)																																																
≥85	2 (0.3)	1 (0.6)	2 (0.8)	3 (0.6)	9 (0.5)																																																

Type of special population	Exposure																																													
	IKEMA (EFC15246): Pharmacokinetics data from IKEMA study confirmed no meaningful impact of age on isatuximab exposure (N = 15, 8.7% of patients in the dataset were ≥75 years of age). No dose adjustments are considered necessary. In addition, no clinically meaningful differences could be seen in safety on the basis of age. IMROZ (EFC12522): Furthermore, the pharmacokinetics data from IMROZ study confirmed no meaningful impact of age on isatuximab exposure (N = 68, 24.2% of patients in the dataset were ≥75 years of age). No dose adjustments are considered necessary. An increase in Grade 5 TEAEs was observed in patients in the IVRd group ≥70 years of age compared to those <70 years of age. This appears to have been due to an increase in COVID-19 related infections during the first two years of the COVID-19 pandemic and may also have been related to imbalances of certain risk factors such as, ISS stage. <table><tr><th colspan="5">SC formulation</th></tr><tr><th></th><th colspan="4">Isatuximab</th></tr><tr><th></th><th>Isa-SC + Pd (N = 307)</th><th>Isa-SC + Kd (N = 74)</th><th>Isa-SC + VRd (N = 141)</th><th>All Isa-SC (N = 522)</th></tr><tr><td>Number of patients treated by isatuximab</td><td>307</td><td>74</td><td>141</td><td>522</td></tr><tr><td colspan="5">Age group (years) (n [%])</td></tr><tr><td><65</td><td>138 (45.0)</td><td>35 (47.3)</td><td>53 (37.6)</td><td>226 (43.3)</td></tr><tr><td>65-74</td><td>107 (34.9)</td><td>29 (39.2)</td><td>63 (44.7)</td><td>199 (38.1)</td></tr><tr><td>75-84</td><td>58 (18.9)</td><td>9 (12.2)</td><td>25 (17.7)</td><td>92 (17.6)</td></tr><tr><td>≥85</td><td>4 (1.3)</td><td>1 (1.4)</td><td>0</td><td>5 (1.0)</td></tr></table> Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study. Note: Percentages are calculated using the number of patients treated as denominator. PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_s_t_x.rtf (06MAY2025 10:44) Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma; Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous; VRd: Bortezomib/Lenalidomide/Dexamethasone. IRAKLIA (EFC15951): Population PK analysis using data from the 5 SC studies with 769 patients aged 31 to 86 years (17.8% and 0.9% of patients in the dataset were ≥75 years and ≥85 of age, respectively) did not identify age as a significant covariate influencing isatuximab PK following SC administration.	SC formulation						Isatuximab					Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)	Number of patients treated by isatuximab	307	74	141	522	Age group (years) (n [%])					<65	138 (45.0)	35 (47.3)	53 (37.6)	226 (43.3)	65-74	107 (34.9)	29 (39.2)	63 (44.7)	199 (38.1)	75-84	58 (18.9)	9 (12.2)	25 (17.7)	92 (17.6)	≥85	4 (1.3)	1 (1.4)	0	5 (1.0)
SC formulation																																														
	Isatuximab																																													
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)																																										
Number of patients treated by isatuximab	307	74	141	522																																										
Age group (years) (n [%])																																														
<65	138 (45.0)	35 (47.3)	53 (37.6)	226 (43.3)																																										
65-74	107 (34.9)	29 (39.2)	63 (44.7)	199 (38.1)																																										
75-84	58 (18.9)	9 (12.2)	25 (17.7)	92 (17.6)																																										
≥85	4 (1.3)	1 (1.4)	0	5 (1.0)																																										
Patients with relevant co-morbidities Patients with hepatic impairment	<table><tr><th colspan="5">IV formulation</th></tr><tr><th colspan="5">Isatuximab</th></tr><tr><td>IVRd (N = 692)</td><td>IKd (N = 177)</td><td>IPd (N = 244)</td><td>Isa (±Dex) (N = 498)</td><td>All (N = 1787)</td></tr></table>	IV formulation					Isatuximab					IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 1787)																														
IV formulation																																														
Isatuximab																																														
IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 1787)																																										

Type of special population	Exposure				
	Number of patients treated by isatuximab				
	6921772444981787				
	Hepatic status (n [%])				
	Normal605 (87.4)160 (90.4)213 (87.3)402 (80.7)1532 (85.7)				
	Mild impairment74 (10.7)15 (8.5)31 (12.7)63 (12.7)203 (11.4)				
	Moderate impairment1 (0.1)2 (1.1)01 (0.2)7 (0.4)				
	Severe impairment1 (0.1)0001 (<0.1)				
	Note: Percentages are calculated using the number of patients treated as denominator.				
	Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN< Total Bilirubin ≤ 1.5 × ULN and AST = Any or Total Bilirubin ≤ ULN and AST >ULN, Moderate: 1.5 × ULN < Total Bilirubin ≤ 3 × ULN and AST = Any, Severe: Total Bilirubin >3 × ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15.				
	PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas				
	OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t.i.rtf (14FEB2024 9:35)				
AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.					
ICARIA (EFC14335): A population PK analysis with data from Phase 1 to 3 studies (N = 476 patients) has demonstrated no effect of mild hepatic insufficiency on isatuximab PK.					
IKEMA (EFC15246): In addition, IKEMA PK data (N = 15, 8.7% of the patients with mild hepatic insufficiency) confirmed no meaningful impact on mild hepatic insufficiency on isatuximab exposure. No dose adjustments are considered necessary in this patient population.					
IMROZ (EFC12522): Furthermore, IMROZ PK data (N = 22, 7.8% of the patients with mild hepatic insufficiency) confirmed no meaningful impact on mild hepatic insufficiency on isatuximab exposure, confirming that no dose adjustment is considered necessary in this patient population.					
SC formulation					
Isatuximab					
Isa-SC + PdIsa-SC + KIsa-SC + VRdAll Isa-SC					
d d (N = 141) (N = 522)					
(N = 307) (N = 74)					
Number of patients treated by isatuximab					
30774141522					
Hepatic status (n [%])					
Normal261 (85.0)65 (87.8)120 (85.7)446 (85.6)					
Mild impairment43 (14.0)9 (12.2)18 (12.9)70 (13.4)					

Type of special population	Exposure																																																											
	<table><tr><td>Moderate impairment</td><td>3 (1.0)</td><td>0</td><td>1 (0.7)</td><td>4 (0.8)</td></tr><tr><td>Severe impairment</td><td>0</td><td>0</td><td>1 (0.7)</td><td>1 (0.2)</td></tr></table> Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study. Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN< Total Bilirubin≤ 1.5 x ULN and AST = Any or Total Bilirubin ≤ ULN and AST >ULN, Moderate: 1.5 x ULN < Total Bilirubin ≤ 3 x ULN and AST = Any, Severe: Total Bilirubin >3 x ULN and AST = Any. PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_s_t.x.rtf (06MAY2025 10:44) Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma; Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous; VRd: Bortezomib/Lenalidomide/Dexamethasone. A population PK analysis with data from 5 Studies (N = 769 patients, including SC and IV data) has demonstrated no effect of has demonstrated no effect of mild hepatic insufficiency on isatuximab PK. Therefore, no dose adjustments are considered necessary in this population after isatuximab SC administration. No conclusion can be drawn for patients with moderate hepatic impairment (data are available for only 2 patients who received with SC administration of isatuximab with Pd).	Moderate impairment	3 (1.0)	0	1 (0.7)	4 (0.8)	Severe impairment	0	0	1 (0.7)	1 (0.2)																																																	
Moderate impairment	3 (1.0)	0	1 (0.7)	4 (0.8)																																																								
Severe impairment	0	0	1 (0.7)	1 (0.2)																																																								
Patients with renal impairment	<table><tr><th colspan="6">IV formulation</th></tr><tr><th rowspan="2"></th><th colspan="5">Isatuximab</th></tr><tr><th>IVRd (N = 692)</th><th>IKd (N = 177)</th><th>IPd (N = 244)</th><th>Isa (±Dex) (N = 498)</th><th>All (N = 178 7)</th></tr><tr><td>Number of patients treated by isatuximab</td><td>692</td><td>177</td><td>244</td><td>498</td><td>1787</td></tr><tr><td colspan="6">Renal status (mL/min/1.73m²) (n [%])</td></tr><tr><td>Normal</td><td>180 (26.0)</td><td>37 (20.9)</td><td>43 (17.6)</td><td>102 (20.5)</td><td>395 (22.1)</td></tr><tr><td>Mild impairment</td><td>316 (45.7)</td><td>83 (46.9)</td><td>98 (40.2)</td><td>191 (38.4)</td><td>774 (43.3)</td></tr><tr><td>Moderate impairment</td><td>131 (18.9)</td><td>39 (22.0)</td><td>87 (35.7)</td><td>143 (28.7)</td><td>447 (25.0)</td></tr><tr><td>Severe impairment</td><td>8 (1.2)</td><td>4 (2.3)</td><td>2 (0.8)</td><td>16 (3.2)</td><td>30 (1.7)</td></tr><tr><td>End stage</td><td>0</td><td>0</td><td>0</td><td>2 (0.4)</td><td>2 (0.1)</td></tr></table>	IV formulation							Isatuximab					IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 178 7)	Number of patients treated by isatuximab	692	177	244	498	1787	Renal status (mL/min/1.73m²) (n [%])						Normal	180 (26.0)	37 (20.9)	43 (17.6)	102 (20.5)	395 (22.1)	Mild impairment	316 (45.7)	83 (46.9)	98 (40.2)	191 (38.4)	774 (43.3)	Moderate impairment	131 (18.9)	39 (22.0)	87 (35.7)	143 (28.7)	447 (25.0)	Severe impairment	8 (1.2)	4 (2.3)	2 (0.8)	16 (3.2)	30 (1.7)	End stage	0	0	0	2 (0.4)	2 (0.1)
IV formulation																																																												
	Isatuximab																																																											
	IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (±Dex) (N = 498)	All (N = 178 7)																																																							
Number of patients treated by isatuximab	692	177	244	498	1787																																																							
Renal status (mL/min/1.73m²) (n [%])																																																												
Normal	180 (26.0)	37 (20.9)	43 (17.6)	102 (20.5)	395 (22.1)																																																							
Mild impairment	316 (45.7)	83 (46.9)	98 (40.2)	191 (38.4)	774 (43.3)																																																							
Moderate impairment	131 (18.9)	39 (22.0)	87 (35.7)	143 (28.7)	447 (25.0)																																																							
Severe impairment	8 (1.2)	4 (2.3)	2 (0.8)	16 (3.2)	30 (1.7)																																																							
End stage	0	0	0	2 (0.4)	2 (0.1)																																																							

Type of special population	Exposure																																																		
	Note: Percentages are calculated using the number of patients treated as denominator. Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN< Total Bilirubin≤ 1.5 × ULN and AST = Any or Total Bilirubin ≤ ULN and AST >ULN, Moderate: 1.5 × ULN < Total Bilirubin ≤ 3 × ULN and AST = Any, Severe: Total Bilirubin > 3 × ULN and AST = Any. Renal status (eGFR, mL/min/1.73m²) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15. PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t.i.rtf (14FEB2024 9:35) AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal. ICARIA (EFC14335): A population PK analysis with data from Phase 1 to Phase 3 studies (N = 476 patients) has demonstrated no effect of mild, moderate and severe renal impairment on isatuximab PK. IKEMA (EFC15246): Pharmacokinetic data from IKEMA study confirmed no meaningful impact of renal function on Isatuximab exposure. However, it could be noted a trend towards lower exposure in the 5 patients with severe renal impairment, but these patients had confounding baseline characteristics that are known to impact isatuximab PK (ie, β2 microglobulin levels at baseline ≥5.5 mg/L with 3 patients were classified ISS III and 2 as ISS II). In addition, no clinically meaningful differences could be seen in safety. Therefore, no dose adjustments are considered necessary in this population. IMROZ (EFC12522): In addition, the pharmacokinetic data from IMROZ study confirmed no meaningful impact of renal function on isatuximab exposure (N = 69;24.6% of the patients with moderate renal insufficiency and N = 5, 1.8% of the patients with severe renal impairment). Except for subsequent events of chronic kidney disease, no clinically meaningful differences could be seen in safety. Altogether, no dose adjustments are considered necessary in this population. <table><tr><th colspan="5">SC formulation</th></tr><tr><th></th><th colspan="4">Isatuximab</th></tr><tr><th></th><th>Isa-SC + Pd (N = 307)</th><th>Isa-SC + Kd (N = 74)</th><th>Isa-SC + VRd (N = 141)</th><th>All Isa-SC (N = 522)</th></tr><tr><td>Number of patients treated by isatuximab</td><td>307</td><td>74</td><td>141</td><td>522</td></tr></table> <table><tr><th>Renal status (mL/min/1.73m²) [n(%)]</th><th>307</th><th>74</th><th>141</th><th>522</th></tr><tr><td>Normal</td><td>307</td><td>74</td><td>141</td><td>522</td></tr><tr><td>Mild impairment</td><td>73 (23.8)</td><td>22 (29.7)</td><td>47 (33.3)</td><td>142 (27.2)</td></tr><tr><td>Moderate impairment</td><td>139 (45.3)</td><td>37 (50.0)</td><td>67 (47.5)</td><td>243 (46.6)</td></tr><tr><td>Severe impairment</td><td>90 (29.3)</td><td>13 (17.6)</td><td>26 (18.4)</td><td>129 (24.7)</td></tr><tr><td>End stage</td><td>5 (1.6)</td><td>2 (2.7)</td><td>1 (0.7)</td><td>8 (1.5)</td></tr></table>	SC formulation						Isatuximab					Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)	Number of patients treated by isatuximab	307	74	141	522	Renal status (mL/min/1.73m²) [n(%)]	307	74	141	522	Normal	307	74	141	522	Mild impairment	73 (23.8)	22 (29.7)	47 (33.3)	142 (27.2)	Moderate impairment	139 (45.3)	37 (50.0)	67 (47.5)	243 (46.6)	Severe impairment	90 (29.3)	13 (17.6)	26 (18.4)	129 (24.7)	End stage	5 (1.6)	2 (2.7)	1 (0.7)	8 (1.5)
SC formulation																																																			
	Isatuximab																																																		
	Isa-SC + Pd (N = 307)	Isa-SC + Kd (N = 74)	Isa-SC + VRd (N = 141)	All Isa-SC (N = 522)																																															
Number of patients treated by isatuximab	307	74	141	522																																															
Renal status (mL/min/1.73m²) [n(%)]	307	74	141	522																																															
Normal	307	74	141	522																																															
Mild impairment	73 (23.8)	22 (29.7)	47 (33.3)	142 (27.2)																																															
Moderate impairment	139 (45.3)	37 (50.0)	67 (47.5)	243 (46.6)																																															
Severe impairment	90 (29.3)	13 (17.6)	26 (18.4)	129 (24.7)																																															
End stage	5 (1.6)	2 (2.7)	1 (0.7)	8 (1.5)																																															

Type of special population	Exposure																																																												
	Note: Isa-SC + Pd: Pooled from EFC15951 study and TCD15484 study in RRMM participants; Isa-SC + Kd: Study ACT17453 in RRMM participants; Isa-SC + VRd: Pooled from IIT17756 study and IIT17041 study in NDMM participants; All Isa-SC: Pooled isatuximab SC treatment in combination of background regimens combining EFC15951 study, TCD15484 study, ACT17453 study, IIT17041 study and IIT17756 study. Note: Renal status (eGFR, mL/min/1.73m2) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15. PGM = PRODOPS/SAR650984/SAR650984SUBQ1/SUBQ1/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_s_t_x.rtf (06MAY2025 10:44) Isa: Isatuximab; Kd: Carfilzomib/Dexamethasone; N: Number of patients; NDMM: Newly Diagnosed Multiple Myeloma; Pd: Pomalidomide/Dexamethasone; RRMM: Relapsed/Refractory Multiple Myeloma; SC: Subcutaneous; VRd: Bortezomib/Lenalidomide/Dexamethasone. TED16414: Pharmacokinetic exposure from 22 patients with ESRD (eGFR <15 mL/min/1.73 m2), were consistent with those from studies ACT15319, ACT15377, ACT15320, and TCD14906 studies (which included isatuximab in combination with cemiplimab in patients with solid tumors, lymphoma or RRMM or istuximab isatuximab monotherapy in RRMM patients) thus indicating no effect of ESRD on isatuximab PK parameters A population PK analysis with data from 5 Studies (N = 769 patients, including SC and IV data) has demonstrated no effect of mild, moderate and severe renal impairment on isatuximab PK. Therefore, no dose adjustments are considered necessary in this population after isatuximab SC administration.																																																												
Patients with significant cardiovascular impairment	Not included in the clinical development program.																																																												
Immunocompromised patients	Not included in the clinical development program.																																																												
Patients with a disease severity different from inclusion criteria in clinical trials	Not included in the clinical development program.																																																												
Populations with relevant different ethnic origin	<table><tr><th colspan="6">IV formulation</th></tr><tr><th></th><th colspan="5">Isatuximab</th></tr><tr><th></th><th>IVRd (N = 692)</th><th>IKd (N = 177)</th><th>IPd (N = 244)</th><th>Isa (+/- Dex) (N = 498)</th><th>All (N = 1787)</th></tr><tr><td>Number of patients treated by isatuximab</td><td>692</td><td>177</td><td>244</td><td>498</td><td>1787</td></tr><tr><td colspan="6">Race (n[%])</td></tr><tr><td>White</td><td>566 (81.8)</td><td>130 (73.4)</td><td>199 (81.6)</td><td>349 (70.1)</td><td>1386 (77.6)</td></tr><tr><td>Black or African American</td><td>4 (0.6)</td><td>5 (2.8)</td><td>6 (2.5)</td><td>25 (5.0)</td><td>53 (3.0)</td></tr><tr><td>Asian</td><td>56 (8.1)</td><td>25 (14.1)</td><td>23 (9.4)</td><td>61 (12.2)</td><td>175 (9.8)</td></tr><tr><td>Other</td><td>9 (1.3)</td><td>3 (1.7)</td><td>2 (0.8)</td><td>21 (4.2)</td><td>36 (2.0)</td></tr><tr><td>Not Reported or Unknown</td><td>57 (8.2)</td><td>14 (7.9)</td><td>14 (5.7)</td><td>42 (8.4)</td><td>137 (7.7)</td></tr></table>	IV formulation							Isatuximab						IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (+/- Dex) (N = 498)	All (N = 1787)	Number of patients treated by isatuximab	692	177	244	498	1787	Race (n[%])						White	566 (81.8)	130 (73.4)	199 (81.6)	349 (70.1)	1386 (77.6)	Black or African American	4 (0.6)	5 (2.8)	6 (2.5)	25 (5.0)	53 (3.0)	Asian	56 (8.1)	25 (14.1)	23 (9.4)	61 (12.2)	175 (9.8)	Other	9 (1.3)	3 (1.7)	2 (0.8)	21 (4.2)	36 (2.0)	Not Reported or Unknown	57 (8.2)	14 (7.9)	14 (5.7)	42 (8.4)	137 (7.7)
IV formulation																																																													
	Isatuximab																																																												
	IVRd (N = 692)	IKd (N = 177)	IPd (N = 244)	Isa (+/- Dex) (N = 498)	All (N = 1787)																																																								
Number of patients treated by isatuximab	692	177	244	498	1787																																																								
Race (n[%])																																																													
White	566 (81.8)	130 (73.4)	199 (81.6)	349 (70.1)	1386 (77.6)																																																								
Black or African American	4 (0.6)	5 (2.8)	6 (2.5)	25 (5.0)	53 (3.0)																																																								
Asian	56 (8.1)	25 (14.1)	23 (9.4)	61 (12.2)	175 (9.8)																																																								
Other	9 (1.3)	3 (1.7)	2 (0.8)	21 (4.2)	36 (2.0)																																																								
Not Reported or Unknown	57 (8.2)	14 (7.9)	14 (5.7)	42 (8.4)	137 (7.7)																																																								

Type of special population	Exposure																								
	<table><tr><th colspan="6">Ethnicity (n[%])</th></tr><tr><td>Hispanic or Latino</td><td>4 (0.6)</td><td>12 (6.8)</td><td>12 (4.9)</td><td>36 (7.2)</td><td>76 (4.3)</td></tr><tr><td>Not Hispanic or Latino</td><td>249 (36.0)</td><td>142 (80.2)</td><td>209 (85.7)</td><td>347 (69.7)</td><td>1083 (60.6)</td></tr><tr><td>Not Reported or Unknown</td><td>439 (63.4)</td><td>23 (13.0)</td><td>23 (9.4)</td><td>115 (23.1)</td><td>628 (35.1)</td></tr></table> Note: Percentages are calculated using the number of patients treated as denominator. Note: Hepatic status is defined as follows, Normal: Total bilirubin ≤ ULN and AST ≤ ULN, Mild: ULN< Total Bilirubin≤ 1.5 × ULN and AST = Any or Total Bilirubin ≤ ULN and AST >ULN, Moderate: 1.5 × ULN < Total Bilirubin ≤ 3 × ULN and AST = Any, Severe: Total Bilirubin >3 × ULN and AST = Any. Renal status (eGFR, mL/min/1.73m2) is defined as follows, Normal: ≥ 90, Mild: ≥ 60 to <90, Moderate: ≥ 30 to <60, Severe: ≥ 15 to <30, End stage renal disease: <15. PGM = PRODOPS/SAR650984/SAR650984POOL5/POOL5/REPORT/PGM/cdc_isa_cat_s_t.sas OUT = REPORT/OUTPUT/cdc_isa_cat_p1_s_t_i.rtf (14FEB2024 9:35). AST: Aspartate Aminotransferase; Dex: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; ULN: Upper Limit of Normal.. ICARIA (EFC14335): Pharmacokinetic analysis with data from Phase 1 to 3 studies (N = 476 patients)) has identified race (Asian versus non-Asian) as a significant covariate influencing isatuximab PK. However, as the impact was limited to V₁ (ie, 24% lower in a typical Asian patient compared to a typical non-Asian patient), it did not translate into a meaningful impact on exposure to require dose adjustment. IKEMA (EFC15246): Data from IKEMA study confirmed no meaningful impact of race (Asian versus non-Asian) on isatuximab exposure (N = 26, 13.2% of the dataset). Data from IMROZ (EFC12522) study confirmed no meaningful impact of race (Asian versus non-Asian) on isatuximab exposure. However, a trend to lower exposure (ie, 28%) was observed in Asian patients (N = 54, 19.2% of the dataset) compared to Caucasian patients. However, there is a trend of a lower exposure in Chinese patients (N = 30) but not in Japanese (N = 17). These Chinese patients had confounding baseline characteristics as these patients presented slightly more advanced disease characteristics (ie, more patients with ISS-III), and slightly lower body weight which may have amplified the effect. IRAKLIA (EFC15951): Population PK analysis with data from 511 Caucasian (66.4% of the population PK data set), 117 Asian (15.2%), 20 Black (2.6%), and 13 patients of other races (1.7%) did not identify race as a significant covariate influencing isatuximab PK following SC administration. This translated into no meaningful difference in exposure across Caucasian, Asian, and Black patients while there was a noticeable lower exposure in 'Other' races after 1400 mg Isa-SC once weekly (QW)/every two weeks (Q2W) in combination with Pd.	Ethnicity (n[%])						Hispanic or Latino	4 (0.6)	12 (6.8)	12 (4.9)	36 (7.2)	76 (4.3)	Not Hispanic or Latino	249 (36.0)	142 (80.2)	209 (85.7)	347 (69.7)	1083 (60.6)	Not Reported or Unknown	439 (63.4)	23 (13.0)	23 (9.4)	115 (23.1)	628 (35.1)
Ethnicity (n[%])																									
Hispanic or Latino	4 (0.6)	12 (6.8)	12 (4.9)	36 (7.2)	76 (4.3)																				
Not Hispanic or Latino	249 (36.0)	142 (80.2)	209 (85.7)	347 (69.7)	1083 (60.6)																				
Not Reported or Unknown	439 (63.4)	23 (13.0)	23 (9.4)	115 (23.1)	628 (35.1)																				

Type of special population	Exposure
Subpopulations carrying known and relevant genetic polymorphisms	Not included in the clinical development program. To date, there is no information suggesting the existence of polymorphism relevant to the efficacy or safety of isatuximab in the currently proposed indication(s).

AST: Aspartate Aminotransferase; COVID-19: Coronavirus Disease 2019; DEX: Dexamethasone; eGFR: Estimated Glomerular Filtration Rate; ECOG: Eastern Cooperative Oncology Group; ESRD: End-Stage Renal Disease; IKd: Isatuximab in combination with Carfilzomib and low-dose Dexamethasone; IPd: Isatuximab in combination with Pomalidomide and Dexamethasone; Isa: Isatuximab; ISS: International Staging System; IV: Intravenous; IVRd: Isatuximab in combination with bortezomib, lenalidomide and dexamethasone; Kd: Carfilzomib/Dexamethasone; Pd: Pomalidomide/Dexamethasone; PK: Pharmacokinetic; RRMM: Relapsed/Refractory Multiple Myeloma; Q2W: Every 2 Weeks; QW: Once Weekly; SC: Subcutaneous; TEAEs: Treatment Emergent Adverse Events; ULN: Upper Limit of Normal; VRd: Bortezomib/Lenalidomide/Dexamethasone.

PART II: MODULE SV - POST-AUTHORIZATION EXPERIENCE

SV.1 POST-AUTHORIZATION EXPOSURE

SV.1.1. Method used to calculate exposure

The MAH is currently utilizing the Margin Consolidated (MARCO) application for reporting of sales data from postmarketing experience since December 2019. .

Methodology.

Total patients exposed were estimated assuming that all vials sold have been used and that each patient, with an average body weight of 73.8 kg, received a mean of nine cycles of chemotherapy with isatuximab at the dosage of 10 mg/kg given four times in first cycle and two times in subsequent cycles and at 89.67% dose intensity, as recommended in the reference document effective during the reference period ie,

Cycle 1: $10 \text{ mg/kg} \times 73.8 \text{ kg} \times 4 \text{ infusions} = 2952 \text{ mg}$.

Cycles 2 to 9: $10 \text{ mg/kg} \times 73.8 \text{ kg} \times 2 \text{ infusions per cycle} \times 8 \text{ cycles} = 11\,808 \text{ mg}$.

A total of 14 760 mg expected per patient for all nine cycles, the total drug received per patient is $14\,760 \times 0.8967$ (dose intensity) equals to 13 235 mg/patient or 13.2 g/patient for all nine cycles. The total number of patients exposed were calculated by dividing total sales in grams with 13.2 g.

SV.1.2. Exposure

Sales figures for the cumulative period were received from MARCO for the period from 01 August 2019¹ through 28 February 2025.

A total of 35 103 patients were exposed worldwide to isatuximab cumulatively.

Cumulative patient exposure are presented in below table.

	ISATUXIMAB						ISATUXIM AB Total
	CONCENTRATE SOLUTION (INFUSION)		INFUSION, LIQUID (SOLUTION)		INJECTION, LIQUID (SOLUTION)		
COUNTRY	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	
████████	0	11	0	0	0	0	11
████████	7084	4486	0	0	0	0	11 570
████████	9067	7547	0	0	0	0	16 614
████████	8178	5756	0	0	0	0	13 934
██████	14 500	6699	0	0	0	0	21 199
████████	47 824	32 788	0	0	0	0	80 612
██████	60	22	0	0	0	0	82

¹ Sales prior to March 2020 correspond to free goods distributed during a temporary authorization to use (authorization to use) procedure in ██████.

	ISATUXIMAB						ISATUXIMAB Total
	CONCENTRATE SOLUTION (INFUSION)		INFUSION, LIQUID (SOLUTION)		INJECTION, LIQUID (SOLUTION)		
COUNTRY	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	
	374	161	0	0	0	0	535
	4142	3590	0	0	0	0	7732
	138	46	0	0	0	0	184
	7125	5448	0	0	0	0	12 573
	78 458	97 374	5883	997	0	0	182 712
	40	54	0	0	0	0	94
	63 660	44 659	0	0	0	0	108 319
	4153	4258	0	0	0	0	8411
	424	420	0	0	0	0	844
	2585	1874	0	0	0	0	4459
	2	2037	0	0	0	0	2039
	860	406	0	0	0	0	1266
	60 331	44 197	0	0	0	0	104 528
	0	0	0	0	177 427	132 589	310 016
	160	137	0	0	0	0	297
	2	2	0	0	0	0	4
	0	60	0	0	0	0	60
	292	1303	0	0	0	0	1595
	64	0	0	0	0	0	64
	765	787	0	0	0	0	1552
	2563	2117	0	0	0	0	4680
	6601	3914	0	0	0	0	10 515
	4440	2999	0	0	0	0	7439
	56	14	0	0	0	0	70
	1709	1062	0	0	0	0	2771
	1840	1748	0	0	0	0	3588
	3791	1936	0	0	0	0	5727
	82	42	0	0	0	0	124
	896	765	167	28	0	0	1856
	60	20	0	0	0	0	80
	28 634	13 993	0	0	0	0	42 627
	105	74	0	0	0	0	179
	1119	2878	0	0	0	0	3997
	906	1077	0	0	0	0	1983
	2717	3018	0	0	0	0	5735
	60 871	37 693	0	0	0	0	98 564
	37	19	0	0	0	0	56
	4143	2521	0	0	0	0	6664
	800	22	0	0	0	0	822
	284	164	0	0	0	0	448
	1386	1433	0	0	0	0	2819
	117 637	77 927	0	0	0	0	195 564

	ISATUXIMAB						ISATUXIM AB Total
	CONCENTRATE SOLUTION (INFUSION)		INFUSION, LIQUID (SOLUTION)		INJECTION, LIQUID (SOLUTION)		
COUNTRY	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	100 MG/5 ML	500 MG/25 ML	
	266 815	167 578	10 965	3525	0	0	448 883
Grand Total	817 780	587 136	17 015	4550	177 427	132 589	1 736 497
Sales in mgs	81 778 000	293 568 000	1 701 500	2 275 000	17 742 700	66 294 500	463 359 700
Total sales in mgs	463 359 700						
Total sales in grams	463 360						
Total patients exposed	35 103						

PART II: MODULE SVI - ADDITIONAL EU REQUIREMENTS FOR THE SAFETY SPECIFICATION

SVI.1 POTENTIAL FOR MISUSE FOR ILLEGAL PURPOSES

A drug abuse liability assessment (DALA) study was not performed with isatuximab as the compound has only a limited ability to cross the BBB with negligible exposure in the brain. Potential for misuse of isatuximab for illegal purposes is considered low as this product is not known to have attributes that make it a candidate for intentional overdose, abuse, or illegal use, such as known pharmacological addictive effects.

PART II: MODULE SVII - IDENTIFIED AND POTENTIAL RISKS

SVII.1 IDENTIFICATION OF SAFETY CONCERNS IN THE INITIAL RMP SUBMISSION

Besides the standard recommendations in the RMP guidance, the following topics were considered as safety concerns because of the nature and mechanism of action of the biological product (IgG mAb), as class effects or because of common concerns in the target population. These safety concerns, however, were assessed as either not relevant to isatuximab based on the currently available clinical evidence or not benefiting from additional pharmacovigilance or additional risk minimization activities. These non-important safety concerns, evaluated in Section [SVII.1.1](#), are as follows:

- Immunogenicity
- Decrease in NK cells
- Intravascular haemolysis
- Infections
- Infusion reactions (IRs) including cytokine release syndrome (CRS)
- Effect on QTc interval
- Respiratory adverse events
- Drug-Drug interactions (DDIs)
- Tumor lysis syndrome (TLS)
- Second primary malignancies (SPMs)

The following safety topics were considered important for inclusion in the list of safety concerns in the initial RMP version 0.1. They are discussed in Section [SVII.1.2](#).

- **Important identified risk**
 - Interference with indirect antiglobulin test (indirect Coombs' test) and possible resulting adverse clinical consequences for the patient (bleeding due to transfusion delay, transfusion haemolysis)
- **Important potential risk**
 - Viral reactivation
- **Missing information**
 - None

SVII.1.1. Risks not considered important for inclusion in the list of safety concerns in the RMP

Reason(s) for not including an identified or potential risk in the list of safety concerns in the RMP

Risks known to be associated with other therapeutic IgG1 mAbs, but assessed as not relevant to isatuximab and its benefit/risk balance, based on the currently available evidence or which would not benefit from additional risk minimization activities or from further evaluation:

- *Immunogenicity:*

In Study EFC14335, no evidence of immunogenicity was demonstrated through ADA positivity. In the clinical experience prior to Study EFC14335, no clinical impact on the risk-benefit profile could be demonstrated. The incidence of treatment emergent ADAs was low (2.3%) and most of these responses were transient, with only 2 out of the 13 treatment-induced ADA positive patients showing persistence (0.35%), in the data pooled across the single agent and combination studies (N = 564).

- *Decrease in NK cells:*

Decrease in NK cells is only one of the laboratory changes observed during immunoprofiling of peripheral blood immune cell subsets during Isa-Pd treatment (eg, also a decrease in neutrophil count - see Module 5.3.5.1 [Study EFC14335] - and an increase in CD3+ T-cells was noted - see Module 5.3.5.3 [tcd14079-immune-biomarker-report]). It is therefore unclear what the isolated effect of decrease in NK cells on the safety profile of the Isa-Pd regimen is. No AE of decrease in NK cells was reported in the isatuximab program.

- *Intravascular haemolysis:*

No red blood cells (RBCs) transfusion-related complications associated with interference for blood typing were reported during any of the clinical trials.

- *Infections:*

In the controlled, randomized Study EFC14335, neutropenia and infections were more frequent in the Isa-Pd arm than in the Pd (control) arm; the incidence of infections leading to definitive treatment discontinuation, or leading to fatal outcome, however, were similar between the treatment arms (2.6% in Isa-Pd versus 4.0% in Pd). When adjusted for the longer duration of exposure in the Isa-Pd arm, the incidence of treatment-emergent serious infections was also similar (0.72 versus 0.67 incidence rate per patient year in the Isa-Pd and Pd arms, respectively). The risk of infections is well recognized, characterized, and adequately managed (with the use of colony stimulating factors, dose reductions of pomalidomide and dexamethasone, and antibiotic/antiviral agents) according to the product information.

- *Infusion reactions including cytokine release syndrome:*

Infusion reactions are well recognized as a very common class effect of mAbs: throughout the isatuximab program, they have occurred in 46.2% of the patients with limited clinical impact: a Grade 3 severity has been reported in 2.6% of the patients, while Grade 4 IRs are uncommon (0.9%). The onset of an IR occurs most frequently (in 97.0% of the patients) at the 1st infusion, and most patients (89.1%) do not experience further episodes at subsequent infusions of isatuximab. Overall, IRs led to dose interruptions of isatuximab in 33.9% of patients and to treatment discontinuation of isatuximab in 3.3% of the patients (required by protocol if Grade 3 or higher). Infusion reactions are well managed with pre-infusion prophylaxis, monitoring of symptoms, and dose interruption, medications, or permanent discontinuation of the treatment.

Thus, the risk of IRs is well-characterized and its management in the target population is well understood, and it would not benefit from additional pharmacovigilance or risk minimization activities besides routine measures.

- *Respiratory adverse events:*

In preliminary non-GLP tissue cross-reactivity studies using a different isatuximab batch and different mAb concentrations, additional staining was also observed in the lung (bronchial epithelium). Staining of all non-lymphoid tissue elements was interpreted as evidence of cross-reactivity, indicating potential unintended off-target sites (see [\[Part II Module SII\]](#)), of isatuximab that included the evaluation of respiratory function before each infusion in the first-in-human Phase 1 single agent trial (TED10893) via the implementation of pulmonary function tests (spirometry, diffusion and capacity) and chest X-rays. In Study EFC14335, notwithstanding a higher incidence of dyspnea in the Isa-Pd arm, the occurrence of clinically meaningful dyspnea was not different between the treatment arms: the incidence of severe dyspnea was not substantially different between the two arms (Grade ≥ 3 : 9.2% in Isa-Pd versus 6.7% in the Pd control arm), and the incidence of serious treatment emergent dyspnea was also not substantially different (2.6% in Isa-Pd versus 1.3% in Pd).

Risk with minimal clinical impact on patients

- Effect on QTc interval:

The potential for an effect on QTc interval was systematically considered as a theoretical risk during the clinical development of isatuximab. (43) Among the completed studies throughout the isatuximab program, no reports of ECG QT interval abnormal, ECG QT prolonged, long QT syndrome, torsade de pointes, or ventricular tachycardia occurred as AEs. Furthermore, a thorough analysis of ECG monitoring data collected in Study TED10893 Phase 1 does not suggest any clinically meaningful QTcF prolongation induced by isatuximab at any dose level.

Other risks considered as not important

- *Drug-drug interactions:*
 - Effect of isatuximab on other drugs: Direct DDI via cytochrome P450 (CYP) enzymes or transporters is not expected because isatuximab is a mAb. However, potential risks of DDI caused by isatuximab due to the alteration of cytokine levels, especially interleukin 6, which has been shown to impact drug metabolizing enzymes, such as CYP enzymes in humans, were taken into consideration. Given the extent and transient nature of isatuximab-induced cytokine elevation, its impact on exposures to CYP450 substrates is likely to be limited. Isatuximab does not alter the pharmacokinetics of lenalidomide, pomalidomide, or cyclophosphamide.
 - Effect of drugs on isatuximab: Isatuximab, a mAb, is likely to be eliminated by proteolytic degradation, thus drugs that impact CYP or transporter expressions are not anticipated to alter the pharmacokinetic of isatuximab. No impact of high dose dexamethasone, lenalidomide/dexamethasone, pomalidomide/dexamethasone, cyclophosphamide/bortezomib/dexamethasone, has been observed on isatuximab pharmacokinetic.

Overall, isatuximab does not alter the pharmacokinetics of, lenalidomide, pomalidomide, or cyclophosphamide and vice-versa, indicating a lack of DDI between isatuximab and these combination drugs.

- *Tumor lysis syndrome:*

The risk of TLS will be closely monitored and further characterized via routine pharmacovigilance activities. No additional pharmacovigilance and/or risk minimization activities is proposed for the risk of TLS. Tumor lysis syndrome is not included in the list of safety concerns in the RMP, consistent with the European Guideline on Good Pharmacovigilance Practices (GVP), Module V Rev. 2.

- *Second primary malignancies:*

The risk of SPMs will be closely monitored and further characterized via routine pharmacovigilance activities. No additional pharmacovigilance and/or risk minimization activities is proposed for the risk of SPMs. Second primary malignancies is not included in the list of safety concerns in the RMP, consistent with the European Guideline on GVP, Module V Rev. 2.

SVII.1.2. Risks considered important for inclusion in the list of safety concerns in the RMP

Table 24 - Important identified risk considered for inclusion in the list of safety concerns: Interference with indirect antiglobulin test (indirect Coombs' test) and possible resulting adverse clinical consequences for the patient (bleeding due to transfusion delay, transfusion haemolysis)

Interference with indirect antiglobulin test (indirect Coombs' test) and possible resulting adverse clinical consequences for the patient (bleeding due to transfusion delay, transfusion haemolysis)	
Scientific evidence that has led to the inclusion	Isatuximab binds to endogenous CD38 found at low levels on RBCs and may interfere with blood bank compatibility testing, including antibody screening and cross-matching. Lack of RBC phenotyping prior to isatuximab treatment could result in delaying a transfusion because of the need to address false positive indirect Coombs' test results. In the case of an urgent transfusion, using non-cross-matched ABO/RhD-compatible RBC could result in a small risk of transfusion-related haemolysis. No RBC transfusion-related complications associated with interference with blood typing were reported during any of the clinical trials.
Risk-benefit impact	Considering the clinical setting in which the patients are being treated, the fact that no haemolysis associated with RBC transfusions has been observed in clinical trials with isatuximab, and consequently the low likelihood of this risk to result in important clinical outcomes, the impact on the risk-benefit balance is deemed to be limited.

CD: Cluster of Differentiation; RBC: Red Blood Cell; RhD: Rhesus Factor D.

Table 25 - Important potential risk considered for inclusion in the list of safety concerns: Viral reactivation

Viral Reactivation	
Scientific evidence that has led to the inclusion	In the case of MM, both the underlying disease and some chemotherapeutic agents used to treat it (such as corticosteroids) may cause immunosuppression that predisposes to viral reactivation. Reactivated viruses may include Herpes zoster or HBV. Hepatitis B Virus reactivation has uncommonly been observed, including fatal cases, for another anti-CD38 mAb which, like isatuximab targets CD38 that is used in similar combination regimens that may cause immunosuppression.
Risk-benefit impact	Given the improved survival outcome in patients with RRMM, it is likely that reactivation of a viral disease will have limited impact on the B/R balance.

B/R: Benefit/Risk; CD: Cluster of Differentiation; HBV: Hepatitis B Virus; mAb: Monoclonal Antibody; MM: Multiple Myeloma; RRMM: Relapsed/Refractory Multiple Myeloma.

SVII.2 NEW SAFETY CONCERNS AND RECLASSIFICATION WITH A SUBMISSION OF AN UPDATED RMP

There are no new safety concerns compared to the previous version of the RMP.

SVII.3 DETAILS OF IMPORTANT IDENTIFIED RISKS, IMPORTANT POTENTIAL RISKS, AND MISSING INFORMATION

The following important risks and missing information have been identified for isatuximab:

- Important identified risk:
 - Interference for blood typing (minor antigen) (positive indirect Coombs' test)
- Important potential risk:
 - Viral reactivation
- Missing information:
 - None

SVII.3.1. Presentation of important identified risks and important potential risks

Table 26 - Important identified risk: Interference for blood typing (minor antigen) (positive indirect Coombs' test)

Important identified risk	Interference for blood typing (minor antigen) (positive indirect Coombs' test)
Potential mechanism	Human RBCs express low levels of CD38 compared to MM cells, and binding of isatuximab to endogenous CD38 has been found on RBCs, causing panreactivity in vitro. (44) Thus, isatuximab may interfere with routine blood bank compatibility tests. This interference is limited to the minor blood groups (not affecting the ABO and Rh typing).
Evidence source(s) and strength of evidence	Class effect: isatuximab binds to RBCs and may interfere with routine blood bank compatibility tests. Interference for blood typing has occurred during clinical trials.

Important identified risk	Interference for blood typing (minor antigen) (positive indirect Coombs' test)
Characterization of the risk	Lack of RBC phenotyping prior to isatuximab treatment could result in delaying a transfusion because of the need to address false positive indirect Coombs' test results. In the case of an urgent transfusion, using non-cross-matched ABO/RhD-compatible RBC could result in a small risk of transfusion-related haemolysis. There is no in vitro hemolytic effect or plasma incompatibility when isatuximab was mixed with human blood in the non-clinical safety studies. In Study ICARIA (EFC14335), the indirect Coombs' test was positive on treatment in 67.7% of the tested Isa-Pd patients; no RBC transfusion complications or haemolysis were observed and no cases of transfusion related haemolysis has been observed. In study IKEMA (EFC15246), the indirect Coombs' test was positive during study treatment in 63.3% of patients among the 150 patients in the Isa-Kd arm with negative test at baseline and at least one test during study treatment. No cases of hemolysis were reported among the patients with positive indirect Coombs' test who received transfusions. In study IMROZ (EFC12522), the indirect Coombs' test was positive during treatment in 136 (51.7%) patients amongst the 222 patients in the IVRd arm with a negative test at baseline and at least one test during study treatment. There were no reports of haemolysis within 8 days of a blood transfusion. A search of the isatuximab GPV database from the IBD of 2-Mar-2020 until 26-Sep-2023 for the SMQ hemolytic disorders retrieved 13 cases (9 unsolicited including 1 literature, and 4 solicited). There was one case of a post-platelet transfusion reaction (transfusion reaction) in [REDACTED] male, with an unknown latency of drugs isatuximab, pomalidomide, dexamethasone. All drugs were continued and the event resolved. This event is not related to this risk which refers to red blood cell reactions. There have therefore been no events fulfilling the criteria for this risk in the postmarketing setting. In study IRAKLIA (EFC15951), a positive indirect Coombs test during study treatment was reported with a higher incidence in the Isa-SC+Pd arm (129 [49.0%] participants) compared with the Isa-IV+Pd arm (99 [37.5%] participants). Most of these were negative at baseline. The additional clinical data did not alter current risk profile. <u>Background incidence/prevalence:</u> Interference and risk of transfusion related haemolysis is specific to human monoclonal IgG1 κ antibody against CD38 antigen, and does not occur in untreated patients with MM. No transfusion-related cases of haemolysis were identified in the global safety database for daratumumab. (45)
Risk factors and risk groups	Patients with MM may require blood transfusions (occurred in 30% of the patients in the isatuximab arm of the study ICARIA (EFC14335), 26% of the patients in the isatuximab arm of the study IKEMA (EFC15246), 20.5% of patients in the isatuximab arm of the study IMROZ (EFC12522) and in the study IRAKLIA (EFC 15951) 11.8% of participants in the Isa-SC+Pd arm and 14.9% of participants in the Isa-IV+Pd arm because of morbidity from MM and its treatment.
Preventability	All the isatuximab study protocols contain instructions about phenotyping of patients before the start of treatment with isatuximab. In the postmarketing setting, educational material distributed to healthcare professionals (HCPs) and blood banks (See [Part V] and [Annex 6] for details) are proposed to increase awareness about the risk of interference and the possible resulting adverse clinical consequences for the patient and provide guidance on how to minimize it: Recommendation for the patients to be blood-typed and screened prior to initiating treatment with isatuximab; phenotyping according to local practice;

Important identified risk	Interference for blood typing (minor antigen) (positive indirect Coombs' test)
	- Use of DTT treated reagent RBCs (44) (or any locally validated methods); - Use of a patient card to inform any HCPs treating a patient that he/she is using isatuximab and that this treatment is associated with the risk of interference.
Impact on the benefit-risk balance of the product	Low impact. No delays in blood transfusions or haemolysis associated with RBC transfusions was observed in clinical trials.
Public health impact	Low impact. No event of haemolysis associated with RBC transfusions have been observed in clinical trials, or the postmarketing setting. Educational materials are provided to HCPs. No significant public health impact is expected.

CD: Cluster of Differentiation; DTT: Dithiothreitol; GPV: Global Pharmacovigilance; HCP: Healthcare Professional; IBD: International Birth Date; IgG: Immunoglobulin G; Isa: Isatuximab; Isa-Kd: Isatuximab/Carfilzomib/Dexamethasone; Isa-Pd: Isatuximab/Pomalidomide/Dexamethasone; IV: Intravenous; IVRd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; MM: Multiple Myeloma; Pd: Pomalidomide/Dexamethasone; RBC: Red Blood Cell; Rh: Rhesus; RhD: Rhesus Factor D; SC: Subcutaneous; SMQ: Standardized MedDRA Query.

Table 27 - Important potential risk: Viral Reactivation

Important potential risk	Viral Reactivation
Potential mechanism	Immunosuppression either by the underlying MM disease process or by the immunosuppressive action of drugs used to MM, such as dexamethasone may predispose to viral reactivation. (46)
Evidence source(s) and strength of evidence	Viral reactivation has been identified for another anti-CD38 antibody approved for the treatment of MM.
Characterization of the risk	No cases of HBV viral reactivation have been observed to date associated with isatuximab in the clinical development program. One case of HBV reactivation was reported from TCD13983 study but on MAH review of the case it was noted that the patient had IgM Hepatitis B antibodies and therefore this was not a reactivation. Herpes zoster was reported in 15 (5.7%) patients receiving isatuximab in the IMROZ (EFC12522) study with similar exposure adjusted rates in the two groups (IVRd vs VRd: 0.017 v 0.20 events per person-years). In the integrated summary of safety analyses, 2.1% of patients (n = 11) in the VRD group and 2.5 % of patients (n = 45) in the "All isatuximab group" (NDMM and RRMM) were reported to have PT: herpes zoster infection. There were an additional two cases of PT: Herpes Zoster disseminated in the All isatuximab group. Cases of other viruses have been observed in patients exposed to isatuximab in the clinical development program (ie, cytomegalovirus, Epstein-Barr virus, adenovirus). A search of the isatuximab safety database from IBD of 2-Mar-2020 until 26-Sep-2023 for the following HLTs: Adenoviral infections; Cytomegaloviral infections; Epstein-Barr viral infections; Herpes viral infections; Papilloma viral infections; Retroviral infections; Polyomavirus infections; Hepatitis virus infections retrieved 69 cases. There were 37 events in 36 case reports of viral reactivation including Herpes Zoster, and including non-sponsored clinical trial reports there were 24 cases (7 solicited Non-sponsored, 7 solicited other, 7 unsolicited non-literature and 3 Japan Non clinical trial solicited). There were 10 cases of CMV reactivation, 1 of Epstein-Barr Reactivation, 7 of Hepatitis B reactivation, 17 Herpes Zoster and 1 of Herpes Simplex reactivation.

Important potential risk	Viral Reactivation
	In one of the 7 cases of Hepatitis B reactivation there were laboratory evidence provided to assess/confirm the diagnosis, the remaining 6 did not provide laboratory evidence to assess/confirm the diagnosis. For one case the regimen was not provided but for the other 6, all were on regimens containing different combinations of dexamethasone, lenalidomide, bortezomib or carfilzomib. In IRAKLIA (EFC 15951: Cytomegalovirus infection reactivation (all grade) – 0.4% (Isa-SC) only leading to dose reduction; Similar incidence of Herpes Zoster (all grade) 0.8% (Isa-IV) vs 1.1% (Isa-SC) and slightly higher incidence of Grade ≥ 3 0% (Isa-IV) vs. 0.8% (Isa-SC) > 0.4% and 0.8% - leading to dose reduction. One case of HBV viral reactivation in China reported after the DLP for the study. <u>Background incidence/prevalence:</u> Viral infections are now the most frequently reported infections in MM (47). Individuals diagnosed with MM are reported to have a 10fold higher risk of developing a viral infection and a 15-fold higher risk of herpes zoster infection compared to general population controls (48). The rate of VZV infection in the daratumumab arms of the pivotal studies for relapsed/refractory myeloma ranged from 2% to 5%. (49) Data on 148 patients from daratumumab clinical trials were combined showed that 2% of patients developed herpes zoster. (50)
Risk factors and risk groups	<u>Documented previous viral exposure:</u> - For HBV: serology; - For Herpes Zoster: clinical evidence of varicella zoster exposure (eg, shingles); - Any other viruses: standard evidence of viral exposure. <u>Immunosuppression:</u> - History of previous treatment with immunosuppressive drugs such as high dose corticosteroids; (46) - Clinical or laboratory data supportive of immunosuppression.
Preventability	- Hepatitis B virus status (by clinical history or previous serology) should be documented at baseline. - For patients with evidence of positive HBV serology, manage according to local or national clinical guidelines; - In patients who develop reactivation of HBV while on isatuximab, suspend treatment with isatuximab and institute appropriate treatment; - Resumption of isatuximab treatment in patients whose HBV reactivation is adequately controlled should be discussed with physicians with expertise in managing HBV. - All known exposures to any viruses capable of reactivation should be documented and managed according to local or national guidelines.
Impact on the benefit-risk balance of the product	Low impact.
Public health impact	Low impact. Hepatitis B virus status can be obtained at baseline and treated according to local and national guidelines. (51) Patients with a history of Herpes zoster or other viruses can be managed according to local or national guidelines.

CD: Cluster of Differentiation; CMV: Cytomegalovirus; DLP: Data Lock Point; HBV: Hepatitis B Virus; HLT: High-level term; IBD: International Birth Date; Isa: Isatuximab; IV: Intravenous; IVrd: Isatuximab in combination with Bortezomib, Lenalidomide and Dexamethasone; MAH: Marketing Authorization Holder; MM: Multiple Myeloma; NDMM: Newly Diagnosed Multiple Myeloma; PT: Preferred Term; SC: Subcutaneous; VRd: Bortezomib/Lenalidomide/Dexamethasone; RRMM: Relapsed Refractory Multiple Myeloma; VZV: Varicella Zoster Virus.

SVII.3.2. Presentation of the missing information

Not applicable

PART II: MODULE SVIII - SUMMARY OF THE SAFETY CONCERNS

Table 28 - Summary of the safety concerns

Important identified risk	Interference for blood typing (minor antigen) (positive indirect Coombs' test)
Important potential risk	Viral reactivation
Missing information	None

PART III: PHARMACOVIGILANCE PLAN (INCLUDING POST-AUTHORIZATION SAFETY STUDIES)

III.1 ROUTINE PHARMACOVIGILANCE ACTIVITIES

The following routine pharmacovigilance activity beyond adverse reactions reporting and signal detection is in place:

- Specific follow-up questionnaire for “Infection”.

III.2 ADDITIONAL PHARMACOVIGILANCE ACTIVITIES

Not applicable since there are no additional pharmacovigilance activities ongoing or planned for this product. Completed post-authorization safety studies (PASS) are presented in [[Annex 2](#)].

III.3 SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES

Not applicable since there are no additional pharmacovigilance activities ongoing or planned for this product.

PART IV: PLANS FOR POST-AUTHORIZATION EFFICACY STUDIES

No imposed post-authorization efficacy studies as a condition of the marketing authorization or which are specific obligations in the context of conditional marketing authorization or marketing authorization under exceptional circumstances are planned or ongoing for isatuximab.

PART V: RISK MINIMIZATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMIZATION ACTIVITIES)

V.1 ROUTINE RISK MINIMIZATION MEASURES

Table 29 - Description of routine risk minimization measures by safety concern

Safety concern	Routine risk minimization activities
Interference for blood typing (minor antigen) (positive indirect Coombs' test)	Routine risk communication: SmPC section 4.5. Routine risk minimization activities recommending specific clinical measures to address the risk: SmPC section 4.4. PL section 2. Other routine risk minimization measures beyond the Product Information: Legal status: Available only on prescription. Isatuximab should be administered by a HCP(SmPC section 4.2).
Viral reactivation	Routine risk communication: SmPC section 4.8. PL section 2. Routine risk minimization activities recommending specific clinical measures to address the risk: SmPC section 4.2 and 4.4. Other routine risk minimization measures beyond the Product Information: Legal status: Available only on prescription. Isatuximab should be administered by a HCP, (SmPC section 4.2).

HCP: Healthcare Professional; PL: Package Leaflet; SmPC: Summary of Product Characteristics.

V.2 ADDITIONAL RISK MINIMIZATION MEASURES

Table 30 - Additional risk minimization measures

HCPs and blood banks brochure	
Objectives	Increase awareness about the risk of interference and its possible adverse clinical consequences for the patient and provide guidance on how to manage it. Re-inforce the communication between HCPs (hematologists, oncologists, nurses etc.), blood transfusion centers/banks, laboratory and patients and share reliable and prompt information.
Rationale for the additional risk minimization activity	Future prescribers/dispensers/other HCPs are not all aware of the risk of interference, its possible adverse clinical consequences for the patient and its management has not become clinical practice everywhere (especially in peripheral centers).
Target audience and planned distribution path	Target audience: HCPs who are expected to prescribe and dispense isatuximab (eg, oncologists, hematologists, nurses etc.).

HCPs and blood banks brochure	
	- Blood banks/transfusion centers. Planned distribution path: - Mail, e-mail or face to face distribution.
Plans to evaluate the effectiveness of the interventions and criteria for success	A PASS survey of effectiveness was conducted between May-2022 and Jun-2023. Based on the PASS survey results, the overall effectiveness of aRMM is considered satisfactory and no change in the current RMS is needed (CHMP Positive Opinion received on 11-Jan-2024).
Patient card	
Objectives	Inform the HCPs/Blood banks treating the patient at any time, including in conditions of emergency, that the patient is using isatuximab and that this treatment is associated with the risk of interference with IAT.
Rationale for the additional risk minimization activity	Ensure that any HCPs/Blood banks treating a patient are aware that the patient is taking isatuximab.
Target audience and planned distribution path	<u>Target audience/ Planned distribution path:</u> Patients will receive the card at the time of the initial dispensation by the treating HCP who will show the card to the patient and explain objective, content and how to use it.
Plans to evaluate the effectiveness of the interventions and criteria for success	A PASS survey of effectiveness was conducted between May-2022 and Jun-2023. Based on the PASS survey results, the overall effectiveness of aRMM is considered satisfactory and no change in the current RMS is needed (CHMP Positive Opinion received on 11-Jan-2024).

aRMM: Additional Risk Minimization Measure; CHMP: Committee for Medicinal Products for Human Use; HCP: Healthcare Professional; IAT: Indirect Antiglobulin Test; PASS: Post-Authorization Safety Study; RMP: Risk Management Plan; RMS: Risk Minimization Strategy.

V.3 SUMMARY OF RISK MINIMIZATION MEASURES

Table 31 - Summary table of pharmacovigilance activities and risk minimization activities by safety concern

Safety concern	Risk minimization measures	Pharmacovigilance activities
Interference for blood typing (minor antigen) (positive indirect Coombs' test)	Routine risk minimization measures: SmPC sections 4.4 and 4.5. PL section 2. Legal status: Available only on prescription. Isatuximab should be administered by a HCP, (SmPC section 4.2). Additional risk minimization measures: Healthcare Professionals and blood banks educational material (brochure) and patient card.	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None

Safety concern	Risk minimization measures	Pharmacovigilance activities
Viral reactivation	Routine risk minimization measures: SmPC sections 4.2, 4.4 and 4.8. PL section 2. Legal status: Available only on prescription. Isatuximab should be administered by a HCP, (SmPC section 4.2). Additional risk minimization measures: None	Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific follow-up questionnaire. Additional pharmacovigilance activities: None

HCP: Healthcare Professional; PL: Package Leaflet; SmPC: Summary of Product Characteristics.

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of risk management plan for SARCLISA (Isatuximab)

This is a summary of the RMP for SARCLISA. The RMP details important risks of SARCLISA how these risks can be minimized, and how more information will be obtained about SARCLISA's risks and uncertainties (missing information).

SARCLISA's SmPC and its PL give essential information to HCP and patients on how SARCLISA should be used.

This summary of the RMP for SARCLISA should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of SARCLISA's RMP.

I. THE MEDICINE AND WHAT IT IS USED FOR

SARCLISA 20 mg/mL concentrate for solution for infusion is authorized in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. SARCLISA 20 mg/mL concentrate for solution for infusion is also indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. SARCLISA 20 mg/mL concentrate for solution for infusion is also authorized in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. SARCLISA 20 mg/mL concentrate for solution for infusion is also indicated in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

SARCLISA 1400/10 mL mg solution for subcutaneous injection is proposed:

- in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.*
- in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.*
- in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.*

- *in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.*

Further information about the evaluation of SARCLISA's benefits can be found in SARCLISA's EPAR, including in its plain-language summary, available on the European Medicines Agency website, under the medicine's webpage:

<https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa>

II. RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERIZE THE RISKS

Important risks of SARCLISA, together with measures to minimize such risks and the proposed studies for learning more about SARCLISA's risks, are outlined in the next sections.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and HCP;
- Important advice on the medicine's packaging;
- The authorized pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (eg, with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In the case of SARCLISA, these measures are supplemented with aRMMs mentioned under relevant important risks, outlined in the next sections.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including periodic safety update report (PSUR) assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of SARCLISA are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of SARCLISA. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (eg, on the long-term use of the medicine).

Table 32 - List of important risks and missing information

Important identified risk	Interference for blood typing (minor antigen) (positive indirect Coombs' test)
Important potential risk	Viral reactivation
Missing information	None

II.B Summary of important risks

Table 33 - Important identified risk with corresponding risk minimization activities: Interference for blood typing (minor antigen) (positive indirect Coombs' test)

Interference for blood typing (minor antigen) (positive indirect Coombs' test)	
Evidence for linking the risk to the medicine	Class effect: isatuximab binds to RBCs and may interfere with routine blood bank compatibility tests. Interference for blood typing has occurred during clinical trials.
Risk factors and risk groups	Patients with MM may require blood transfusions (occurred in 30% of the patients in the isatuximab arm of the study ICARIA (EFC14335), 26% of the patients in the isatuximab arm of the study IKEMA (EFC15246) and 20.5% of patients in the isatuximab arm of study IMROZ (EFC12522), because of morbidity from MM and its treatment.
Risk minimization measures	Routine risk minimization measures: SmPC sections 4.4 and 4.5. PL section 2. Legal status: Available only on prescription. Isatuximab should be administered by a HCP (SmPC section 4.2). Additional risk minimization measures: Healthcare Professionals and blood banks educational material (brochure) and patient card.

HCP: Healthcare Professional; MM: Multiple Myeloma; PL: Package Leaflet; RBC: Red Blood Cell; SmPC: Summary of Product Characteristics.

Table 34 - Important potential risk with corresponding risk minimization activities: Viral reactivation

Viral reactivation	
Evidence for linking the risk to the medicine	Viral reactivation has been identified for another anti-CD38 antibody approved for the treatment of MM.
Risk factors and risk groups	<u>Documented previous viral exposure:</u> • For HBV: serology; • For Herpes Zoster: clinical evidence of Herpes simplex exposure (eg, shingles); • Any other viruses: standard evidence of viral exposure. <u>Immunosuppression:</u> • History of previous treatment with immunosuppressive drugs such as high dose corticosteroids; (46) • Clinical or laboratory data supportive of immunosuppression.

Viral reactivation	
Risk minimization measures	Routine risk minimization measures: SmPC sections 4.2, 4.4 and 4.8. PL section 2. Legal status: Available only on prescription. Isatuximab should be administered by a HCP, (SmPC section 4.2). Additional risk minimization measures: None

CD: Cluster of Differentiation; HBV: Hepatitis B Virus; HCP: Healthcare Professional; MM: Multiple Myeloma; PL: Package Leaflet; SmPC: Summary of Product Characteristics.

II.C Post-authorization development plan

II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorization or specific obligation of SARCLISA.

II.C.2 Other studies in post-authorization development plan

There are no studies for SARCLISA.

REFERENCES

1. Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. Non-communicable Disease Global Health Research Group, Association of Pacific Rim Universities. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. *Lancet Haematol*. 2022 Sep;9(9):e670-7.
2. Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. *BMC Cancer*. 2021 May 25;21(1):606.
3. Schey SA, Morris J, Maguire A, Dhanasiri S. Quantifying the Burden of Multiple Myeloma Across Europe. *Blood*. 2016 Jan 1;128(22):5960.
4. Leleu X, Gorsh B, Bessou A, Paka P, De Nascimento J, Colin X, et al. Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database. *Eur J Haematol*. 2023 Jul;111(1):125-34.
5. Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. *Cancer*. 2023 Jul 1;129(13):2023-34.
6. D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. *J Clin Oncol*. 2022 Oct 10;40(29):3406-18.
7. International Agency for Research on Cancer. Multiple myeloma fact sheet, Globocan 2020 [Internet]. Lyon: IARC; 2020 [cited 2024 Jan 12]. Available from: <https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf>
8. Li J, Smith A, Crouch S, Oliver S, Roman E. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN). *Cancer Causes Control*. 2016 Aug;27(8):1019-26.
9. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. *Med Sci (Basel)*. 2021 Jan 20;9(1):3.
10. Sun T, Wang S, Sun H, Wen J, An G, Li J. Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. *Leuk Lymphoma*. 2018 Jan;59(1):49-58.
11. Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, et al. Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. *Clin Lymphoma Myeloma Leuk*. 2015 Oct;15(10):563-77.

12. Paydas S. Management of hemopoietic neoplasias during pregnancy. *Crit Rev Oncol Hematol*. 2016 Aug;104:52-64.
13. He J, Schmerold L, Van Rampelbergh R, Qiu L, Potluri R, Dasgupta A, et al. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma. *Adv Ther*. 2021 Jan;38(1):640-59.
14. Gordan LN, Tan CR, Vescio R, Ye JC, Schinke C, Medhekar R, et al. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study. *Clin Lymphoma Myeloma Leuk*. 2023 Sep 14:S2152-2650(23)01550-1.
15. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Electronic address: guidelines@ehaweb.org; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021 Mar;32(3):309-22.
16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Multiple myeloma. Version 1.2024 [Internet]. Plymouth Meeting (PA): NCCN; 2023 [cited 2023 Sep 23]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
17. Hemminki K, Hemminki J, Försti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. *Leukemia*. 2023 Apr;37(4):854-63.
18. Gaisan CM, Buendía B, Escalante F, Garcia EG, Grande M, Naves A, et al. Clinical and Demographic Characteristics of Multiple Myeloma Patients at Study Enrollment: Analysis of Dorian Study (NCT:04659798). *Blood* 2022; 140 (Suppl 1): 12528–29.
19. Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, et al. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum. *Int J Hematol*. 2023 Nov;118(5):609-17.
20. Lin HM, Davis KL, Kaye JA, Luptakova K, Nagar SP, Mohty M. Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. *Adv Hematol*. 2019 Jan 29;2019:4625787.
21. Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et al. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. *Sci Rep*. 2020 Apr 6;10(1):5991.
22. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. *Blood Cancer J*. 2022 Jan 31;12(1):21.

23. Facon T, Kumar SK, Plesner T, Orłowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021 Nov;22(11):1582-96.
24. Facon T, Kumar S, Plesner T, Orłowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med.* 2019 May 30;380(22):2104-15.
25. Chen T, Fallah M, Brenner H, Jansen L, Mai EK, Castro FA, et al. Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. *Sci Rep.* 2016 Feb 24;6:22084.
26. Jonsdottir G, Lund SH, Björkholm M, Turesson I, Hultcrantz M, Porwit A, et al. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. *Blood Adv.* 2017 Nov 22;1(25):2392-98.
27. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. *Ann Oncol.* 2017 Feb 1;28(2):228-45.
28. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. *Clin Infect Dis.* 2009 Oct 15;49(8):1211-25.
29. Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, et al. Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma. *Medicine (Baltimore).* 2015 Dec;94(50):e2305.
30. Turesson I, Björkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. *Eur J Haematol.* 2018 Apr 20;101(2):237-44.
31. Langseth OO, Myklebust TA, Johannesen TB, Hjertner O, Waage A. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. *Br J Haematol.* 2020 Nov;191(3):418-25.
32. A Monnereau, S Guyader-Peyrou, M Maynadie, X Troussard. Survival of people with cancer in metropolitan France, 1989-2013. Part 2 - Malignant hemopathies. INVS reports. (Available on request)
33. Gregersen H, Vangsted AJ, Abildgaard N, Andersen NF, Pedersen RS, Frolund UC, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. *Cancer Med.* 2017 Jul;6(7):1807-16.
34. Sverrisdottir IS, Rognvaldsson S, Thorsteinsdottir S, Gislason GK, Aspelund T, Turesson I, et al. Comorbidities in multiple myeloma and implications on survival: A population-based study. *Eur J Haematol.* 2021 Jun;106(6):774-82.

35. Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. *Eur J Haematol.* 2016 Nov;97(5):416-29.
36. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. *Cancer Treat Rev.* 2015 Dec;41(10):827-35.
37. Cockayne DA, Muchamuel T, Grimaldi JC, Muller-Steffner H, Randall TD, Lund FE, et al. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. *Blood.* 1998 Aug 15;92(4):1324-33.
38. Kato I, Yamamoto Y, Fujimura M, Noguchi N, Takasawa S, Okamoto H. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, $[Ca^{2+}]_i$, and insulin secretion. *J Biol Chem.* 1999 Jan 22;274(4):1869-72.
39. Sun L, Iqbal J, Dolgilevich S, Yuen T, Wu X-B, Moonga BS, et al. Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption. *FASEB J.* 2003 Mar;17(3):369-75.
40. Kim S, Kim T, Lee HR, Jang EH, Ryu HH, Kang M, et al. Impaired learning and memory in CD38 null mutant mice. *Mol Brain.* 2016 Feb 9;9:16.
41. Higashida H, Lopatina O, Yoshihara T, Pichugina YA, Soumarokov AA, Munesue T, et al. Oxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout mice. *J Neuroendocrinol.* 2010 May;22(5):373-79.
42. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, et al. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. *Int J Toxicol.* 2009 May-Jun;28(3):230-53.
43. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use [Internet]. USA: ICH;2005. ICH Harmonized Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs-E14 [cited 2019 Apr 3]. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
44. Final report of resolving the isatuximab interference with blood compatibility testing. 2019 Mar 7.
45. Brilhante D, Chabert T, Brites A, Nascimento F, Rodrigues-Jose M, Duran-Antonio J, et al. Management of daratumumab interference in Portuguese blood transfusion medicine: A literature review about unmet needs and challenges. *Int J Blood Transfus Immunohematol.* 2018;8.
46. Asthana A, Lubel J. Reactivation of latent viruses after treatment with biological therapies. *Virus Adaptation and Treatment.* 2014 Jun;6:1-10.

47. Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):444-50.e3.
48. Teh BW, Slavin MA, Harrison SJ, Worth LJ. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev Anti Infect Ther. 2015;13(11):1325-36.
49. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Oct 6;375(14):1319-31.
50. Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One. 2019 Feb 13;14(2):e0211927.
51. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215-9.

PART VII: ANNEXES

ANNEX 4 SPECIFIC ADVERSE DRUG REACTION FOLLOW-UP FORMS

TABLE OF CONTENTS

SPECIFIC FOLLOW-UP QUESTIONNAIRE FOR INFECTION



Isatuximab (Sarclisa®) – Infection Follow-up Questionnaire (FUQ)

The goal of this questionnaire is to collect essential information on reported events of **infection** with **isatuximab (Sarclisa®)**. For any other additional adverse event(s), please complete the corresponding “other experienced adverse event(s)” section at the end of this form.

By providing this information, you will make a useful contribution to the safety of this product for the benefit of patients.

Sanofi Case ID:	Program ID:
Reporter Information (person who provides the information reported on this form):	
Name or Initials:	
Qualification: ☐ Health Care Professional (HCP) ☐ Non-HCP	
Email address:	Phone Number:
Patient Information:	
Name or Initials or ID:	Gender: ☐ Male ☐ Female ☐ Unknown
Date of Birth:	Age or Age Group:

PRODUCT(S) INFORMATION	
Isatuximab (Sarclisa®)	
Date of commencing isatuximab (DD/MM/YYYY)	
Date of last isatuximab injection prior to event (DD/MM/YYYY)	
Isatuximab batch number at time of event occurrence (if known)	

ADVERSE EVENT(S) INFORMATION	
Final Diagnosis: _____	Date: _____
Suspected Etiology	
Event Relationship to Isatuximab: ☐ Not Related ☐ Related ☐ Unknown	
If <u>not</u> related, please indicate the suspected etiology of the infection adverse event:	
Event Seriousness	
☐ Non-Serious (<u>none</u> of the following criteria) ☐ Serious (<u>select at least one criterion below</u>):	
☐ Death Date of Death: _____ Autopsy Performed: ☐ No ☐ Yes ☐ Unknown	
☐ Hospitalization or Prolongation of Hospitalization Duration of Hospitalization: _____	
☐ Persistent or Significant Disability or Incapacity ☐ Life-Threatening ☐ Medically Significant (as per HCP)	
☐ Suspected Transmission of Infectious Agent ☐ Congenital Anomaly / Birth Defect	
Action(s) Taken with Isatuximab	
☐ Dose Not Changed ☐ Dose Reduced ☐ Drug Interrupted ☐ Drug Withdrawn ☐ Unknown ☐ N/A ☐ Other (specify below)	
If applicable, please provide the date that isatuximab was altered or stopped (DD/MM/YYYY): _____	
If isatuximab was stopped, did infection improve or resolve after stopping? ☐ No ☐ Yes ☐ Unknown ☐ N/A	
If isatuximab was stopped, was isatuximab later reintroduced? ☐ No ☐ Yes (specify below) ☐ Unknown ☐ N/A	
If applicable, please provide the date that isatuximab was reintroduced (DD/MM/YYYY): _____	
If isatuximab was reintroduced, did infection reoccur after reintroduction? ☐ No ☐ Yes ☐ Unknown ☐ N/A	

Treatment For Infection and/or Its Complications

☐ Treatment was NOT provided
 ☐ Treatment was provided (specify below)
 ☐ Unknown

If applicable, please specify the treatment(s) provided below [medication(s), dose(s), and date(s)]:

Event Outcome

☐ Recovered/Resolved Date: _____
 ☐ Recovered/Resolved with Sequelae (specify sequelae): _____ Date: _____
 ☐ Fatal
 ☐ Unknown

☐ Not Recovered/Not Resolved
 ☐ Recovering/Resolving
 ☐ Other (specify): _____

PATIENT INFORMATION

Medical History		Start Date (if applicable) (DD/MM/YYYY)	Stop Date (if applicable) (DD/MM/YYYY)
History of cytomegalovirus (CMV) infection	☐ No ☐ Yes		
History of hepatitis (A, B, or C)	☐ No ☐ Yes		
History of herpes zoster (shingles) or received the herpes zoster vaccine	☐ No ☐ Yes		
History of herpes simplex (cold sores or genital herpes)	☐ No ☐ Yes		
Recent exposure to individuals with CMV, hepatitis, herpes zoster, or herpes simplex	☐ No ☐ Yes		
History of autoimmune disease or diagnosis of HIV/AIDS	☐ No ☐ Yes		
History of chronic liver disease or abnormal liver function tests in the past year	☐ No ☐ Yes		
History of diabetes	☐ No ☐ Yes		
History of chronic kidney disease	☐ No ☐ Yes		
Major surgeries in the past six months or history of blood transfusions in the past year or history of organ transplant	☐ No ☐ Yes		
Pregnancy status	☐ No ☐ Yes		
Recent travel to areas with high prevalence of infections such as hepatitis A or E	☐ No ☐ Yes		
If "Yes" was selected for any of the above, please provide additional details (e.g., disease and information) below:	Any other medical history or risk factor [specify, with date(s)]:		

ADDITIONAL INFORMATION

Please provide any other relevant additional information **regarding the reported event** (e.g., other suspect product(s), other additional information on reported adverse event including signs or symptoms, patient's medical history, concomitant medications, etc.):

Please provide the relevant laboratory data, including, depending on the event, a complete blood count, HBsAg, HBeAg, anti-HBs, Total anti-HBc, IgM anti-HBc, HBV DNA, anti-HCV, hepatitis C RNA, CMV IgM and IgG, CMV PCR (DNA), HSV IgM and IgG, HSV PCR (DNA), and VZV IgM and IgG, VZV PCR (DNA). Please provide results for the relevant tests: 1) before isatuximab initiation (baseline values), 2) after isatuximab initiation but before infection event, 3) during infection event, 4) at recovery/outcome of event.

Please provide relevant information regarding **any other experienced adverse event(s)** (e.g., event onset date(s), outcome(s), if it led to hospitalization, relationship(s) with Sanofi product, etc.):

Additional requests for the reporter (if any):

ANNEX 6 DETAILS OF PROPOSED ADDITIONAL RISK MINIMIZATION ACTIVITIES

Key messages of the additional risk minimization measures

Prior to the use of SARCLISA[®] in each Member State the Marketing Authorization Holder (MAH) must agree about the content and format of the educational program, including communication media, distribution modalities, and any other aspects of the program, with the National Competent Authority.

The educational program is aimed at:

- increasing the awareness about the risk of interference **for blood typing (minor antigen) (positive indirect Coombs test)** and its possible adverse clinical consequences for the patient;
- providing guidance on how to manage it and;
- at re-inforcing the communication between healthcare professionals (HCPs) and patients and share reliable and prompt information.

The MAH shall ensure that in each member state where SARCLISA is marketed, all HCPs who are expected to prescribe/dispense SARCLISA and blood banks/transfusion centers are provided with the following educational package to be disseminated through professional bodies:

- Healthcare professionals and blood banks educational material
- Patient card (for HCPs prescribing/dispensing SARCLISA)

1. HCPS AND BLOOD BANKS EDUCATIONAL MATERIAL

The HCPs and blood banks educational material includes the following elements:

- The summary of product characteristics (SmPC)
- The HCPs and blood banks brochure
- Patient card

1.1 Healthcare professionals and Blood Banks brochure

The HCPs and Blood Banks brochure will contain the following key information:

Relevant information of the safety concern “Interference for blood typing (minor antigen) (positive indirect Coombs test)”:

- Isatuximab binds to CD38 on red blood cells (RBCs) and may result in a false positive indirect antiglobulin test (indirect Coombs test).
- The determination of a patient’s ABO and Rh blood type are not impacted.

Details on how to minimize the safety concern addressed by the additional risk minimization measure through appropriate measures:

- All patients should be blood typed and screened prior to start treatment with isatuximab. Phenotyping may be considered prior to starting isatuximab treatment as per local practice.

- The interference with the indirect Coombs test may persist for at least 6 months after the last isatuximab infusion therefore the HCP should advise the patient to carry the patient card until at least 6 months after the treatment has ended.
- The interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt isatuximab binding or other locally validated methods. Since the Kell Blood group system is also sensitive to DTT treatment, Kell-negative units should be supplied after ruling out or identifying alloantibodies using DTT-treated RBCs.
- In case of urgent need for transfusion, non-cross matched ABO/Rh compatible RBC units can be administered as per local bank practices.
- In the event of a planned transfusion, the HCPs should notify blood transfusion centres about the risk of interference with indirect antiglobulin tests.
- Emphasize the need to consult the SmPC.
- Instruct the HCP regarding the need to give the patient card to the patients and to advise them to consult the package leaflet (PL).

1.2 Patient Card

The patient card will contain the following brief and concise information regarding the risk of “Interference for blood typing (minor antigen) (positive indirect Coombs test)” both for patients and HCPs consulted by the patient:

- A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using SARCLISA (isatuximab), and that this treatment is associated with the important identified risk of Interference for blood typing (minor antigen) (positive indirect Coombs test), which may persist for at least 6 months after the last isatuximab infusion.
- A clear reference that the patient should continue to carry this card until at least 6 months after the treatment has ended.
- Contact details of the prescriber and the patient.